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ABSTRACT

REGULATION OF THE RETINOBLASTOMA TUMOR SUPPRESSOR BY THE
NOVEL RAS EFFECTOR NORE1A
Thibaut François Barnoud
November 9, 2015

Ras is the most frequently mutated oncogene in human cancers. It acts as a critical branch
point in signal transduction, regulating numerous downstream effectors involved in cell
growth and differentiation. While Ras has the capacity to activate many growth
promoting pathways, it can paradoxically regulate growth inhibitory pathways leading to
apoptosis and cell cycle arrest. One of the ways Ras can inhibit the growth of cells is via
a family of effectors called the RASSF proteins. One of the members of this family,
RASSF5, also known as Novel Ras Effector 1A (NORE1A), is a tumor suppressor that is
frequently inactivated in human tumors by epigenetic mechanisms. NORE1A binds
directly to Ras, and it promotes the growth inhibitory properties of Ras by activating a
tumor suppressive function called oncogene induced senescence. We have recently
shown in the laboratory that NORE1A serves as a senescence effector of Ras by
activating the p53 tumor suppressor. However, knockdown of p53 using siRNA
technology did not completely abrogate the ability of NORE1A to induce senescence,
vi

suggesting that there may be additional mechanisms by which NORE1A promotes
senescence. The other well characterized pathway involved in Ras-induced senescence is
the Rb pathway. Using immunoprecipitation techniques, we show that NORE1A forms
an endogenous, Ras regulated complex with the Rb phosphatase PP1A, and that
Ras/NORE1A promote the stability of the PP1A protein. Furthermore, our results show
that NORE1A scaffolds PP1A to Rb in a Ras dependent manner, in turn promoting the
dephosphorylation of Rb, a pro-senescent event. Using western blot analysis, we found
that NORE1A can also regulate non-phosphorylation post-translational modifications of
Rb, including its acetylation and SUMOylation. Using commercially available
senescence detection kits, we found that loss of Rb significantly suppressed the ability of
NORE1A to induce senescence in both murine and human systems. Collectively, our
work strongly suggests that NORE1A is a double barreled Ras senescence node,
explaining why Ras driven tumors often show loss of NORE1A expression.
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CHAPTER 1

BACKGROUND AND INTRODUCTION

1.1 – Overview:

Cancer is the second leading cause of death among Americans, only after heart
disease (1). More importantly, one of every four deaths in the United States is due to
cancer (2). This disease is projected to reach healthcare costs of over 200 billion dollars
by 2020 (3), highlighting the urgency not only for improved cancer therapies, but
discovering novel and innovative treatments for currently undruggable cancers.
Ultimately, the solution may lie in unraveling the complexities of cancer progression and
gaining a better understanding of tumor development.
It is widely believed that in order for a normal cell to transform into a cancer cell,
genes that regulate growth and differentiation must be altered. Cancer can be caused by
alterations in oncogenes, tumor suppressor genes, and microRNAs (4). It was
hypothesized over thirty years ago that cells contain proto-oncogenes, genes that are
involved with normal aspects of behavior, and that such proto-oncogenes might be
mutated to give rise to oncogenes. In turn, these oncogenes have the ability to convert
normal cells into cancer cells (5).
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Some of the most significant and well-characterized proto-oncogenes in human
cancer are the three Ras proto-oncogenes. Mutations in one of these three genes can give
rise to a constitutively active Ras protein. Such mutations can be a critical step in tumor
initiation and development, because aberrant Ras signaling will continuously activate
downstream effector pathways involved in growth, differentiation, and cell survival (6).
Recent advances in genetic technology have enabled researchers to examine the true
significance of Ras in cancer: over one third of all human cancers contain activating point
mutations in the Ras gene (7). From an oncogenic standpoint, Ras can regulate numerous
growth promoting pathways, including the classic trio of Ras effector pathways Raf,
phosphoinositide 3-kinase (PI3K), and ral guanine nucleotide dissociation stimulator
(RalGDS) (7-9). Furthermore, functional studies have shown that at least six Ras effector
signaling pathways are involved in either the initiation or the maintenance of Ras driven
cancers (10).
However, counterintuitive evidence dating as far back as the early 1980s pointed
to the notion that Ras does not exclusively promote the growth of cells (11). It has now
become clear that while oncogenic Ras can promote transformation by regulating
numerous growth promoting pathways, Ras can paradoxically promote apoptosis and
senescence (12). However, the mechanisms by which Ras can inhibit the growth of cells
are poorly understood. More recent evidence has implicated the RASSF family of tumor
suppressors as negative effectors of Ras (13). RASSF5, or Novel Ras Effector 1A (which
from this point forward will be referred to as NORE1A), was the first identified member
of the RASSF family, and has been shown to bind directly to Ras (14) in order to activate
Ras mediated growth inhibitory pathways. More importantly, loss of NORE1A
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expression due to epigenetic mechanisms can be found in a variety of different tumors
(15), supporting its role as a tumor suppressor.
Initial evidence of NORE1A acting as a tumor suppressor was quite strong. First,
transient over-expression of NORE1A can lead to apoptosis (16). Second, restoring
NORE1A expression in a NORE1A negative cell line was shown to inhibit its
transforming phenotype (17). And in some cases, restoring NORE1A expression in
tumors that have lost NORE1A expression can significantly diminish the tumorigenic
phenotype (16). This work, along with data showing that the dysregulation of NORE1A
is implicated in a rare familial cancer syndrome (18), confirms that NORE1A is a bona
fide tumor suppressor. While NORE1A has now been shown to have powerful tumor
suppressive functions, in part by regulating the p53 and HIPPO tumor suppressor
pathways (12,19,20), the significance of NORE1A as a negative effector of Ras is only
partially understood.
Recent evidence showed that NORE1A is critical senescence effector of Ras, in
part by activating the pro-senescent post-translational modifications of p53 (20). But, in
addition to p53, Ras can promote senescence by activating the Retinoblastoma (Rb)
protein, a tumor suppressor believed to be inactivated directly or indirectly in virtually all
human cancers (21). Rb is primarily activated by dephosphorylation, and phosphatases
such as PP1A promote the activation of Rb by dephosphorylation (22). Interestingly,
PP1A was detected in complex with NORE1A in a yeast two-hybrid screen (23). Using
state of the art biological techniques, including immunoprecipitations, western blot
analysis, luciferase assays, and senescence assays, we sought out to determine if Ras
could regulate Rb via its effector NORE1A. The collective work and data depicted in this
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dissertation highlights the discovery of a novel signaling pathway by which Ras and
NORE1A cooperate to suppress growth by activating the tumor suppressive functions of
Rb, in turn promoting the onset of cellular senescence. Here, we will show that NORE1A
can bind to and stabilize PP1A. This interaction is significantly enhanced by Ras, in turn
allowing PP1A to activate Rb by promoting its dephosphorylation, a pro-senescent event
(24). Furthermore, we show that NORE1A requires Rb in order to fully promote its
senescent function.
This work identified a further mechanism by which NORE1A can promote
oncogene induced senescence caused by activated Ras. After characterizing the role of
NORE1A mediated dephosphorylation of Rb, we decided to investigate the potential for
NORE1A to alter additional post-translational modifications of Rb. Initial experimental
work found that Ras/NORE1A enhanced the total levels of Rb acetylation, currently
thought to be an activating event, in part by maintaining Rb in its active, dephosphorylated state. We go on to show that Ras/NORE1A can also modulate the
SUMOylation of Rb. While the biological significance of this Rb modification remains
unclear, this is the first line of evidence showing that Ras can regulate the SUMOylation
of downstream targets using effector proteins such as NORE1A.
We also present evidence that, in addition to affecting the post-translational
modifications of Rb, NORE1A also seems to stabilize Rb. Thus, we identify a novel
function for NORE1A, acting as a Ras regulated scaffolding molecule to enhance PP1A
binding to Rb to promote its activation, in turn promoting the induction of senescence.
This finding could have a significant impact, based on the notion that, depending
on its regulatory molecules, PP1 can form stable complexes with as many as 650
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mammalian proteins (25). Furthermore, we have provided evidence suggesting that Ras
can regulate both the acetylation as well as the SUMOylation machinery, in addition to
its proto-typical ability to affect protein function by phosphorylation and dephosphorylation events. These additional findings could have major ramifications as to
how Ras can regulate protein function on multiple levels, and that the code of posttranslational modifications regulated by Ras could have adverse effects on protein
localization, stabilization, and activity.

1.2 – The Ras Oncogene:

The Ras genes may be the most well characterized oncogenes in human cancer
(26). High frequency of Ras mutations occurs in a wide spectrum of human cancers,
including three of the four most deadly cancers in the US (lung, colon, and pancreatic
cancer) (27), highlights the importance of Ras as an integral component of tumorigenesis.
Here, we provide a chronology of the most important discoveries regarding Ras protein
structure and function, the activation and regulation of Ras, the mechanisms of Ras signal
transduction, both growth promoting and tumor suppressive, and its implications in
cancer.

1.2.1 – The Discovery of Ras:

The identification of Ras emerged during the extensive study of acutely
transforming retroviruses from mice, rats, cats, and chickens (28). The path to the
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discovery of Ras began in 1964, when Jennifer Harvey discovered that preparing a
murine leukemia virus, obtained from a leukemic rat, and injecting it into newborn
rodents would induce sarcomas (29). The Kirsten-MSV (murine sarcoma virus) was
identified in 1967 by serial passaging of murine leukemia viruses through Wister-Furth
rats (30). It was not until 1975 that Scolnick et al. showed that these viral strains were
recombinant viruses that carry sequences derived from the rat genome. These findings,
work that many at the time thought to be irrelevant to human cancer, provided the first
line of evidence of what were termed oncogenic genetic elements (28). Unfortunately, the
realization that human cancers are not initiated by transforming retroviruses dampened
enthusiasm.
These genes, termed Ras for rat sarcoma virus, were identified in the human
genome in 1982. Three groups made the simultaneous discovery that transforming genes
introduced by DNA transfection assay into NIH/3T3 cells were the same Ras genes
identified earlier in the Kirsten and Harvey sarcoma viruses (31-33), and that the
transforming effects were caused by a missense mutation in the Ras gene (34-37).
Furthermore, the identification of mutant Ras genes in patient tumors but not in normal
tissues was an important validation that the Ras mutations identified in cell culture were
not just artifacts of cell passaging in vitro (28). While these discoveries were critical for
unraveling the concept that mutations can turn proto-oncogenes into oncogenes and in
turn play a significant role in tumor development, they fail to address how Ras functions,
how it can be regulated, or the mechanism of signal transduction from Ras to downstream
effectors.
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1.2.2 – Ras and Cancer:

As the most commonly mutated oncogene in cancer, Ras has been thought of as
the “Holy Grail” of cancer drug development (38). Early experimental work was slow
and complicated due to the fact that Ras is controlled through several different positive
and negative regulators and can act upon numerous downstream effectors, each with a
defined pattern of tissue-specific expression and distinct set of intracellular functions.
Initial investigations to understand the roles of activated Ras showed that oncogenic
alleles contained a very specific set of point mutations.
Mammalian Ras genes acquire transformation-inducing properties by single point
mutations with their coding sequences. Mutations in naturally occurring Ras oncogenes
have been localized in codons 12, 13, 59, and 61 (37). In addition, in vitro mutagenesis
studies have shown that mutations in codons 63, 116, and 119 can also confer
transforming properties to Ras genes (39-41). Interestingly, the presence of a glycine
residue at position 12 appears to be necessary for the normal function of Ras proteins, as
it has been shown that substitution of Gly-12 by any other amino acid (with the exception
of proline) results in the oncogenic activation of Ras (42). Second, substitution of Gly-13
also has transforming consequences for the harboring cells, though not all substitutions
appear to have the same activating effect (39,43). Third, substitution of Gln-61 by any
other amino acid residue, except Pro-61 and Glu-61, yields oncogenic Ras (44). The
effects of other point mutations of Ras are less understood, though have been shown to
turn Ras into an oncogene. Unlike the retroviral Ras oncogenes, which exhibit two
mutations, all cellular Ras oncogenes only carry a single activating mutation (45). By
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1983, all three members of the Ras family had been identified (46). Similar to H-Ras and
K-Ras, the newly identified N-Ras was also found to contain activating point mutations
in certain human tumors (47).
After the initial discovery of the Ras oncogene, reports began to surface noting
that certain types of human cancers were specifically associated with a small number of
specific mutations in the reading frame of the Ras gene. The most frequent Ras mutations
are found in K-Ras, and they are frequently observed in pancreatic (48) and colon cancers
(49). Second, N-Ras mutations were primarily associated with lymphoid malignancies
(43,50-53) and melanomas (54). Lastly, H-Ras mutations were mostly associated with
bladder carcinomas (55), though such mutations are found much less frequently
compared to K- and N-Ras mutations. It was later found that mutations in Ras occur in
approximately one third of all human tumors, with the highest incidence in the pancreas
(90%), colon (50%), thyroid (50%), lung (30%) and leukemia (30%) (56).

1.2.3 – Regulation of Ras Activation:

Once the significance of Ras in cancer was discovered, work began to shift
towards understanding how Ras functions to promote cancer and how it can be regulated.
Ras proteins have since then been shown to bind guanine nucleotides and possess
intrinsic GTPase activity (57). The biochemical properties of Ras proteins closely
resemble those of the G proteins involved in the modulation of signal transduction
through transmembrane signaling systems (58). The bound guanine moiety determines
the activity of G proteins: when a G protein is bound to a GTP molecule, the protein is
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typically in the active conformation. However, heterotrimeric G proteins were known to
possess an intrinsic GTP hydrolysis activity (which from this point forward will be
referred to as GTPase activity) (Figure 1). Thus, in order to regulate its activity, the G
protein will hydrolyze GTP into GDP, in turn shuttling itself into an inactive
conformation. This on/off switch is critical for the proper regulation of G proteins such as
Ras, and reactivation occurs when the GFP is exchanged for a GTP molecule, which is
typically more abundant in the cell (57).
Further evidence showed that mutations of the Ras gene can cause the Ras
oncoprotein to behave differently than their normal counterparts (59-61). The observation
that many oncogenic mutants of Ras are reduced in GTPase activity led to the initial
belief that Ras mediated transformation occurred as a result of the impaired intrinsic
GTPase activity of Ras (59-62); however, this theory would eventually be proven wrong.
Analysis of GTPase activities associated with a large number of Ras mutants failed to
reveal a quantitative relationship between GTPase activity and transforming potential
(44,63-65). The notion that mutant Ras was only about 8-fold less active than wild-type
Ras had many speculating if this was sufficient to account for its transforming power
(66). Work performed by Trahey and McCormick went on to show that a GTPase
activating protein (GAP) allows normal Ras proteins to turn themselves off efficiently by
greatly enhancing the GTPase activity of Ras, whereas oncogenic Ras proteins stay
locked in the active, GTP-bound form (67). Contrary to the initial hypothesis, it is the
resistance to GAPs that leaves Ras proteins permanently GTP bound. Thus, the resistance
to GAP activity is far more critical for Ras transformation than its own intrinsic GTPase
activity.
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Copyright Permissions not required for this type of use.
<http://medicinembbs.blogspot.com/2011/02/essential-alterations-for-malignant.html>

Figure 1: Model for Ras Activation. Mitogenic stimuli, such as growth factors, can
regulate the activity of Ras, which is predominantly found on the inner leaflet of the
plasma membrane. Ras can act as a critical branch-point in signal transduction: the GTPbound form is active while the GDP-bound form is inactive. GTP loading caused by
guanine nucleotide exchange factors (GEFs) induces a conformational change in Ras that
allows it to bind effectors via their Ras-binding domains. In its GTP-bound form, Ras
interacts with and regulates numerous downstream effectors, such as MAPK. Ras can be
inactivated by its intrinsic GTPase activity, which can be accelerated by the binding of
GTPase activating proteins (GAPs). This converts GTP back to GDP, returning Ras to
the off conformation.
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1.2.4 – Post-Translational Modifications of Ras:

Extensive work using deletion mutants of mammalian Ras genes has led to the
identification of the carboxyl terminal sequence Cys186-A-A-A-X-COOH (68).
Interestingly, it was shown around that time that Ras proteins have been localized to the
inner side of the plasma membrane (69). More importantly, mutants lacking Cys-186
code for proteins that remain in the cytosol and cannot induce transformation of NIH3T3
cells, suggesting that this post-translational modification is required for the proper
biological function of Ras (70). Interestingly, blocking C-terminal modifications of
human H-Ras using C-terminal antibodies impaired normal GTP-binding function (71),
validating the notion that the C-terminal processing and subsequent recruitment of Ras to
the membrane is required for proper Ras function.
Even though the Ras family members show some differences in sequence
homology in the C-terminus, it has been shown that they all contain a consensus CAAX
sequence at the C-terminus (72-74), where C is a cysteine residue, A is aliphatic, and X is
any amino acid (75). This C-terminal domain acts as a key regulator of Ras function, in
part by playing a role in proper localization of Ras to the inner leaflet of the plasma
membrane (76). The mechanism and sequence of events for Ras localization to the cell
membrane was elucidated in the early 1990s. First, a farnesyl pyrophosphate group is
covalently attached to a cytosolic Ras protein by an enzyme called farnesyltransferase
(77-79). Second, Ras-converting enzyme 1 (RCE1) causes a proteolytic cleavage of the
last three amino acids of Ras. Third, isoprenylcysteine carboxyl methyltransferase 1
(ICMT1) methylates the last Cysteine residue. And lastly, an enzyme called
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palmitoyltransferase (PTase) transfers an additional palmitoyl group to the Cysteine
residue upstream of the C-terminus, in turn allowing for proper insertion of Ras into the
inner cell membrane (80).
As was the case with the complexity of GTPase regulation of Ras activity, the
post-translational modifications of Ras proteins involved in recruitment of Ras to the cell
membrane were also not straight-forward. Further evidence pointed to additional
mechanisms for full recruitment of Ras to the cell membrane (80). Some isoforms of Ras
(including H-Ras, N-Ras, and K-Ras 4A) required additional palmitoyl groups to be
attached to the C-terminal cysteine residue before being able to be attached to the cell
membrane; however, K-Ras-4B does not have any palmitoylation at all, but rather
contains a string of positively charged Lysine residues (known as the polybasic region)
found upstream of the C-terminus that are sufficient to attach Ras to the membrane (81).

1.2.5 – Growth Promoting Pathways of Ras:

The discovery of Ras behaving as a critical oncogene to drive cancer development
dates back to the early 1980s. This led to an onslaught of research to try and understand
the biological processes that are regulated by Ras. Studies done in 1984 showed that
treatment with epidermal growth factor (EGF) led to an increase in the GTPase activity of
H-Ras (82). This was the first line of evidence pointing to Ras being involved in
regulation of growth pathways. These findings, along with other work implicating Ras
regulation by other growth factors and cytokines, suggest that just like prototypical G
proteins, Ras can behave as a signal transduction molecule (83-86). The GTP-bound form
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of Ras is in the active form by virtue of its increased affinity for effectors; more
importantly, there are at least eleven distinct classes of Ras effectors that have so far been
identified (10), with the majority of these effectors possessing either Ras-binding
domains (RBD) or Ras-association (RA) domains (87). Association with Ras-GTP
promotes effector activation by increasing the concentration of effectors at the plasma
membrane, where additional events facilitate activation or enhance catalytic activity (10).
The role of Ras in signal transduction was largely undefined in the early to mid
1980s, though it had clearly been established as a regulator of cell growth and
differentiation. However, work done by Bar-Sagi and colleagues in 1986 showed that
microinjection of Ras protein into rat embryonic fibroblasts led to a significant increase
in the activation of phospholipase A (88), an enzyme known to hydrolyze phospholipids
into fatty acids and is involved in the production of arachinodic acid. Further work led to
the concept of Ras effector signaling pathways: evidence shown in 1988 by Fukami et al.
demonstrated that inhibition of phosphatidylinositol 4,5-bisphosphate (PIP2) caused
reversible and dose-dependent decrease in proliferation and reversion of cell morphology
of Ras-transformed cells (89). Furthermore, work performed by Feramisco and
colleagues implicated the kinase Raf as a downstream effector of Ras, though the
connection between Ras and Raf was not defined (82). Due to the development of yeast
two-hybrid technology, it was later shown that the interaction between Ras and Raf was
direct (90). This was the first true line of evidence implicating Ras in signal transduction,
suggesting that Ras is directly interacting with its effector proteins to regulate
downstream signaling cascades. As a whole, Ras regulates numerous growth promoting
pathways, including the Raf/MEK/Erk, PI3K/AKT, and the Ral-GDS pathways
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(collectively known as the classical Ras pathways). The Ras effector signaling pathways
are critical for Ras biology, and ongoing efforts over the past thirty years have begun to
decipher the molecular web of Ras signaling.

1.2.5.1 – Raf/MEK/Erk Pathway:

The first Ras effector pathway to be identified was the RAF-MEK-Erk pathway
(90-93). Activation of the pathway begins with Ras activation. Classically, an
extracellular signal binds to a protein tyrosine kinase receptor, such as epidermal growth
factor receptor (EGFR) or the platelet-derived growth factor receptor (PDGFR), in turn
inducing the oligomerization of the receptor (94). This leads to the allosteric activation of
the intracellular tyrosine kinase (95,96), resulting in the cross-phosphorylation of the
receptors. The phospho-tyrosines in the intracellular domain can now serve as docking
sites for adaptor proteins (97). Adaptor proteins such as Grb2 can now recognize SH2
domains and recruit guanine-nucleotide exchange factors (GEFs), such as Sos, to the
membrane (98). The GEF is able to activate membrane-associated Ras by converting it
from its inactive GDP-bound form to its active GTP-bound form. GTP binding promotes
a conformational change permitting Ras to associate with downstream effectors. Raf is
then recruited to the cell membrane and is activated via its interaction with Ras (99).
Raf is the best characterized Ras effector and is considered an oncogene in its
own right. Raf is a member of a family of serine/threonine kinases that include Raf-1, ARaf and B-Raf. Raf activation by Ras stimulates a kinase cascade by phosphorylation of
MAPKK (also called MEK in mammalian systems), in turn activating downstream
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proteins Erk1 and Erk2 (MAPK). Activation of kinases Erk1 and Erk2 by MEK can
phosphorylate and activate a number of nuclear transcription factors, other kinases,
among many other proteins. Interestingly, many of the MEK/Erk targets have been
implicated in Ras-induced cellular transformation (100).
For many years, the Raf oncogenes were not thought to be frequently mutated in
human cancer, as aberrant activation of the Raf pathway was dedicated to Ras mutations,
which can regulate both the Raf and the PI3K pathways (101). More extensive studies
have now shown that it is not necessary to have mutated Ras in order to have aberrant
Raf signaling. Recent work has shown that B-Raf is reported to be mutated in
approximately 7% of all cancers, and is commonly found in melanoma (~30 to 70%),
thyroid cancer (~35 to 50%), colorectal cancer (~5 to 20%), and ovarian cancer (~30%)
(102).
While it is clear that Raf is a critical effector of Ras and is involved in Ras
mediated cellular transformation via MEK/Erk, activation of the Raf proteins is very
complex as there are many phosphorylation sites on Raf, and Raf activation/inactivation
depends in large part on its phosphorylation status (101). While the kinases involved in
the regulation of the Raf/MEK/Erk pathway have been extensively studied, the
knowledge of phosphatases involved in these regulatory events remains poorly
understood. In addition, it has now been shown that Raf has roles outside of the canonical
MEK/Erk downstream effectors, some of which involve the prevention of apoptosis. To
make matters more complicated, it has been shown that the Raf/MEK/Erk pathway can
paradoxically effect cell cycle arrest differentiation, and senescence (103,104). Thus, the
Raf/MEK/Erk pathway seems to have some opposing functions, adding to the complexity
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of its regulation. What is clear is that Raf is a critical downstream effector of Ras by
binding directly to Ras; furthermore, Raf preferentially binds to the active, GTP bound
form of Ras, further validating the role of Raf as a bona fide Ras effector (93).

1.2.5.2 – PI3K/AKT Pathway:

One of the best characterized Ras effector families is the PI3K family, of which
the members play important roles as mediators of Ras mediated cell survival and
proliferation (105,106). The PI3K family of enzymes is organized into 3 main classes
(class I, II, and III). Interestingly, Ras is able to interact with the different isoforms of
class I PI3Ks, which is the most well characterized family and the one most clearly
implicated in human cancer (107). PI3-kinase catalyzes the conversion of
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate
(PIP3), which binds the pleckstrin homology (PH) domain of Akt, stimulating its kinase
activity (108). Akt activation controls signaling pathways regulating different cellular
processes such as cell survival, glucose uptake, and glycogen metabolism. Specifically,
Akt promotes cell survival primarily by inhibiting the pro-apoptotic Bcl-2 family
members BAD and BAX (109,110). Second, Akt can promote an increase in transcription
of anti-apoptotic and pro-survival genes by negatively regulating the transcription factor
NF-κB (111). Third, Akt can phosphorylate Mdm2, an event that antagonizes p53mediated apoptosis (108). In addition to Akt activation, PI3K can also activate the Rac
GTPase, an important mediator of oncogenic Ras transformation (112).
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Although the importance of Ras proteins in developmental processes is clear, the
oncogenic potential of constitutively activated Ras proteins and its implication in cancer
has drawn far more attention. Interestingly, aberrant PI3K signaling is one of the most
frequent occurrences in human cancer (110,113). In addition, it has been shown that PI3K
signaling is indispensable to maintain transformed growth in Ras mutant cell lines both in
vitro and in xenografts in mice. Although multiple Ras effectors are essential to initiate
tumor formation, only signaling through the PI3K/Akt pathway seems to be necessary to
maintain tumor growth (114). By increasing the ability for growth and by decreasing the
capacity for apoptosis, PI3K signaling supports tumorigenesis. More importantly, mice
with mutations in the PI3K catalytic subunit p110α, which blocks its ability to interact
with Ras, are highly resistant to endogenous oncogenic K-Ras-induced tumorigenesis and
H-Ras-induced skin carcinogenesis (106,108).
The Ras/PI3K pathway has also been implicated in cancer metastasis, the leading
cause of death in cancer patients. Ras activates Rac via PI3K, and Rac regulation of actin
reorganization and membrane ruffling can promote increased cell motility and contribute
to tumor cell invasion and metastasis (115). Furthermore, oncogenic Ras and PI3K can
promote the loss of anchorage-dependent growth, which is a key feature needed for tumor
cells to form metastases (116-118).

1.2.5.3 – Ral-GDS Pathway:

The third classical Ras effector pathway involves the Ral-GEF proteins. RalGEF
members (RalGDS, RGL, RGL2, and RGL3) link Ras proteins to activation of the RalA
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and RalB small GTPases (119). Activation of Ral allows it to interact with its
downstream effectors, including Sec5, RalBP1, and ZONAB, though it is likely that there
are additional protein partners not yet identified. Through these interactions, Ral proteins
can regulate a wide array of cellular functions, such as proliferation, migration, and
vesicle sorting (120). Ral can also control gene expression through transcription factors
like fos, jun, AFX, and ZONAB.
RalGDS was discovered in 1994 in a yeast two-hybrid screen performed in
multiple labs (121). RalGDS was found to catalyze nucleotide exchange on both RalA
and RalB, but not on other small GTPases such as the Ras, Rho, and Rab families (122).
Therefore, activation of RalGDS by Ras ultimately results in the activation of Ral.
Activated Ral can in turn bind to several downstream effectors involved in critical
biological processes, including actin organization, cytokinesis, autophagy, gene
transcription, cell proliferation, cell survival, and secondary messenger production (122).
The biological function of RalGDS, as well as the other Ral-GEF family
members, is not fully understood, although there is evidence that they play an important
role in Ras mediated transformation in vivo (123,124). Work performed by GonzalezGarcia and colleagues showed that mice lacking RalGDS show reduced tumor incidence,
size, and progression in a skin cancer model where H-Ras was the primary driver (124).
They went on to show that RalGDS was required for skin tumor formation through
mediation of JNK/SAPK pathway.
Collectively, the initial evidence pointed to the idea that the activation of the Ral
pathway alone has a weak oncogenic effect, but can complement the roles of other Ras
effectors in promoting cell transformation in tissue culture (124). However, it has
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recently been argued that the role of the Ral pathway in Ras dependent transformation
could be more critical in human cells compared to rodent fibroblasts. When work
performed by Counter and colleagues explored the role of Ral in Ras mediated growth
transformation of immortalized human astrocytes, fibroblasts, or epithelial cells, a more
prominent role for Ral GTPases as effectors of Ras in human cancer was observed (125).
More importantly, work done by Hamad and colleagues made the striking observation
that of the three best studied Ras effectors – Raf, PI3K, and RalGEF – that RalGEF was
the most important in inducing human cells to proliferate in suspension (125). This result
was unexpected because previous experiments in mouse cells had identified Raf as the
most oncogenic (120). Ultimately, the evidence points to the RalGDS pathway as playing
a far more significant role in human systems. While a lot of uncertainty remains in how
RalGDS directly functions in Ras mediated transformation, Ral GTPase signaling has
now emerged as being critical in both normal and neoplastic cell physiology (122).

1.2.5.4 – Additional Ras Pathways:

Apart from the above-mentioned Ras effectors, an increasing number of
molecules that specifically interact with Ras have been described (108). Some of the
additional Ras effectors identified include phospholipase C, T-Cell lymphoma invasion
and metastasis 1 (TIAM1), and Ras interaction/interference 1 (RIN1), all of which add
complexity and significance for Ras in signal transduction and cellular transformation.
The ground-breaking work of Illenberger and colleagues was the first line of
evidence implicating small GTPases in inositol lipid signaling (126,127). Additional
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work went on to show that there are at least three different PLC isozymes (PLC-β2, -γ2,
and -ɛ) that are robustly activated by Ras (128), though it seems that PLCɛ may be the
one most implicated in Ras mediated transformation. PLCɛ is a key mediator of calcium
signaling, in part via the activation of Protein Kinase C (PKC) which allows for the
release of calcium from the endoplasmic reticulum (128). Interestingly, recent evidence
has provided a link between PLCɛ and tumor development. It has been shown that PLCɛ
deficient mice are resistant to skin tumor formation in a chemical carcinogen-induced
model (129). Additional evidence also points to PLCɛ increasing tumor formation by
increasing important inflammatory responses in dermal fibroblasts (130). In addition to
its link with tumorigenesis, there is now evidence showing that PLCɛ contains a CDC25
domain, also referred to as a RasGEF domain, theoretically placing PLCɛ upstream of
Ras, suggesting a potential positive feedback loop for PLCɛ signaling (131). As a whole,
the work involving the Ras/PLCɛ pathway has shown its importance in signal
transduction and tumor development. While PLCɛ has been shown to contain two Cterminal RA domains and binds directly to Ras (132), many questions still remain
unanswered as to the potential mechanisms by which it directly affects Ras mediated
transformation.
T-Cell lymphoma invasion and metastasis-inducing 1 (TIAM1), a Rac-specific
guanine nucleotide exchange factor, was first identified for invasiveness in mouse
leukemia cells (133). It mediates a broad range of cellular processes, including cellular
migration and adhesion (134). It has been reported that over-expression of TIAM1 is
correlated with poor prognosis in patients with hepatocellular carcinoma (135), and
additional reports have now shown that alterations in TIAM1 expression/function may
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contribute to tumorigenesis and carcinoma progression of common types of cancer (136139). Interestingly, TIAM1 preferentially associates with activated GTP-bound Ras
through a Ras-binding domain; this was shown to promote the activation of Rac in a
PI3K-independent manner (140). Just as with the Ras/PLCɛ pathway, the Ras/TIAM1 is
not fully understood, though it is likely that Ras mediated activation of Rac via TIAM1
will have important ramifications on a number of biological processes, such as motility,
growth, and invasion.
The Ras interaction/interference 1 (RIN1) protein was initially identified as a Ras
effector in 1991 (141), and was later shown to bind directly to Ras (142,143). Recent
work done by Wang and colleagues has shown that RIN1 has high-affinity for binding to
Ras and also demonstrated that this binding directly competes with Raf1 (144). Most
striking was RIN1 could inhibit cellular transformation by activated mutant Ras, thereby
distinguishing RIN1 from other Ras effectors that enhance transformation (144). In
addition to competing with Raf for binding to Ras, it has been proposed that RIN1 also
functions by promoting endocytosis of Ras-stimulating growth factor receptors, such as
EGFR (145). Thus, it seems that RIN1 behaves as a tumor suppressor by negatively
regulating Ras function. This hypothesis was validated by work showing that loss of
RIN1 can be found in breast tumor cell lines and that restoring RIN1 expression blocked
anchorage-independent growth in vitro and tumor formation in vivo (146). Collectively,
this was a critical discovery, suggesting that RIN1 was the first identified Ras binding
partner that could antagonize Ras mediated transformation (142). This was the first line
of evidence suggesting that effector signaling pathways regulated by Ras do not
exclusively promote cellular growth and transformation.
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1.2.6 – Growth Inhibitory Pathways:

Recently, there has been an appreciation that Ras, and other oncogenes,
paradoxically induce both pro- and anti-apoptotic signaling (147), and that the outcome
of these contradictory signals greatly depends on the cell type and context (148). The
balance of positive and negative signals depends on a number of different parameters,
including kinetics, stoichiometry, availability of different binding partners, and activation
of other similar or countervailing forces (148) (Figure 2). Currently, it is believed that in
normal cells, a constitutively high level of activated Ras induces a protective, proapoptotic response to prevent oncogenesis (148). However, oncogenic Ras is likely to
promote growth and differentiation in cells that have lost functional growth inhibitory
pathways. Thus, Ras activates contradictory intracellular pathways, depending on cell
context, that modulate cell viability (149).
It has been known for quite some time that powerful, innate mechanisms exist that
restrain oncogenic potential (147). The first line of evidence in favor of this theory, at
least for Ras, was published in 1983, when Newbold and Overell showed that in normal
cells, oncogenic Ras triggered a profound growth arrest resembling replicative
senescence (11). However, Ras could transform these fibroblasts if the cells had been
newly immortalized by carcinogens, validating the claim that Ras is protective against
oncogenesis in normal cells but oncogenic in nature in transformed cells. Future work has
now shed some light on how Ras negatively regulates growth. Though the mechanisms
remain relatively unclear, Ras can regulate at least two growth inhibitory pathways:
apoptosis and senescence.
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Figure 2: Ras paradoxically regulates both growth promoting and inhibitory
pathways. Oncogenic Ras, depending on the cell context and cell type, can regulate both
pro-growth and tumor suppressive pathways. In many cases, Ras activates cell
proliferation by regulating the Raf, PI3K, and RalGDS pathways to promote growth and
differentiation. However, signaling via the negative Ras effectors, including the RASSF
family and MST kinases, can lead to apoptosis, cell cycle arrest, and induction of cellular
senescence. It is thought that the loss of these functional growth inhibitory pathways is
what drives Ras towards transformation.
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1.2.6.1 – Apoptosis:

The identification of RIN1 as a potential negative effector of Ras intensified
research toward the potential of Ras negatively regulating the growth of cells. It has been
shown that RIN1 binds to activated Ras with a similar affinity to that seen by Raf1, and
that RIN1 can inhibit cellular transformation caused by activated Ras (144). Additional
findings in the 1990s validated the notion that Ras may able to regulate growth inhibitory
properties of cells. First, constitutive expression of oncogenic Ras in a number of cell
lines, including Jurkat (human T lymphoblastoid cell line) and murine fibroblasts,
rendered cells susceptible to apoptosis following suppression of protein kinase C activity
(150,151). Second, di Jeso and colleagues showed that serum withdrawal induces
apoptotic cell death in K-Ras transformed cells, but not in normal differentiated thyroid
cells (152), suggesting that oncogenic Ras was directly involved in serum-depleted
induced apoptosis. In addition, cells over-expressing Crk-II, an adapter protein that
regulates Ras activation, undergo apoptosis after serum-deprivation in a Ras dependent
manner (153). Therefore, induction of apoptosis by Ras may be an important factor in
limiting the expansion of somatic cells that sustain oncogenic Ras mutations (149).
While several independent studies had clearly highlighted a novel role for Ras in
the regulation of apoptosis, the molecular mechanisms by which Ras could activate
apoptotic signals were not completely understood, though it was clear that the ultimate
outcome of pro-apoptotic Ras signals depends greatly on the cell type and context (148).
This claim was based upon the notion that the Raf pathway, initially shown to promote
growth, can actually be either anti- or pro-apoptotic depending on the circumstances

24

(148). However, this remains somewhat controversial, and it is still quite unclear exactly
how the Raf pathway can differentiate between pro and anti-apoptotic signals. Thus, the
focus of Ras mediated apoptosis switched toward potential negative effectors of Ras,
especially after the discovery of RIN1. Interestingly, not long after the identification of
RIN1, another family of negative Ras effectors was discovered that was believed to be
the missing link between Ras and growth inhibition: the RASSF family.

1.2.6.2 – Ras-Induced Senescence:

Cellular senescence was first described over forty years ago by Hayflick and
colleagues, who showed that normal cells had a limited ability to proliferate in culture
(154). They described that the remaining cells, over many cell doublings, remained viable
for many weeks, but failed to grow despite the presence of ample space, nutrients, and
growth factors in the medium (155). A senescent cell is a cell that has exited the cell
cycle permanently and is incapable of resuming proliferation, even upon mitogenic
stimuli (156,157). Some of the key characteristics of senescent cells include a typical flat
and enlarged morphology, many (but not all) cell types acquire resistance to certain
apoptotic signals, altered gene expression, and other senescence markers, such as
senescence-associated β-galactosidase positivity (155,158). An enormous breakthrough
occurred in 1997, when Serrano and colleagues showed that ectopic expression of
oncogenic Ras in normal fibroblasts resulted in a permanent cell cycle arrest and a drastic
increase in senescent cells (159). This work eventually led to the concept that has since
been named “oncogene induced senescence.” While oncogene induced senescence was
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first seen upon ectopic expression of activated Ras, it was later shown that ectopic
expression of other oncogenes, such as E2F1, Raf, mos, cdc6, and cyclin E had very
similar effects (160-162). Collectively, the evidence strongly suggests that aberrant
mitogenic signaling in primary cells could lead to permanent cell cycle arrest and cellular
senescence; more importantly, recent studies have now clearly established the role of
cellular senescence as a potential tumor suppressor mechanism in vivo (158). Thus,
oncogene induced senescence is widely believed to be a critical fail-safe mechanism that
has been developed to suppress cell proliferation caused by aberrant activation of oncoproteins in normal cells (163).
The mechanisms by which oncogenic Ras can promote the induction of
senescence are slowly being discovered, but are quite complex and remain unclear.
Initially, one of the hallmarks of cells undergoing oncogene induced senescence was the
involvement of the p53 and the Rb pathways (164) (Figure 3). Oncogenic Ras alone has
been shown to transform primary mouse fibroblasts that are deficient for either functional
p53 or Rb pathways (165,166). However, induction of senescence in human cells seems
more complex: evidence suggests that activation of both the p53 and the Rb pathways is
essential for induction of senescence in a variety of human cell strains (164), and this
may be due in part because of potential for cross-talk between the two pathways in
human cells. While both pathways have consistently been shown to be vital for the proper
activation of the senescent phenotype, it is worth noting that recent work performed by
Wei and colleagues has shown that Rb is clearly required in human cells for Ras to
induce senescence (167,168). Ultimately, Ras-induced senescence is circumvented by
inactivating the p53 and Rb pathways.
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Figure 3: Pathways involved in oncogene induced senescence. Ras-induced
senescence is thought to function as a critical barrier against aberrant Ras signaling that
would normally promote uncontrolled cell growth. While the mechanisms involved in
Ras-induced senescence are not fully understood, it is clear that Ras activates senescence
via the p53 and Rb tumor suppressor pathways. Loss of these functional pathways allows
Ras to bypass senescence induction and in turn promote transformation.
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While the understanding of the significance of oncogene induced senescence as a
critical barrier for tumor development grew, the mechanisms by which it occurs remains
elusive. Additional evidence collectively showed that Ras-induced senescence truly
involved an intricate web of multiple signaling mechanisms, including ATM, Arf, p16,
p38, and FOXO (169). However, all of these mechanisms still ended up merging toward
the two classical senescence pathways, p53 and Rb. Even though there was compelling
evidence that Ras was promoting the induction of senescence through the p53 and Rb
pathways, there was very little evidence linking Ras directly to these pathways. The
hypothesis was that, similar to Ras mediated apoptosis, Ras was able to regulate
senescence induction through its potential negative effectors. This hypothesis remained
hanging in the balance, until the discovery of the RASSF family of tumor suppressors.

1.3 – The RASSF Family of Tumor Suppressors:

Evidence highlighting growth inhibitory functions of Ras pointed to the
possibility that Ras may have unidentified negative effectors that regulate such functions.
One of the ways this question was addressed was by performing large yeast two-hybrid
screens as an attempt to discover novel binding partners of Ras. Ras contains several
well-characterized binding domains, including the RBD and the RA domain. As a result,
such two-hybrid screens would specifically focus on individual binding sites of Ras. In
1998, a potential Ras effector was newly identified by Vavvas and colleagues, which they
termed NORE1 for novel Ras effector 1 (14). Two years later, a large scale data base
search led to a second potential Ras effector, called RASSF1 (170). Over time, the

28

RASSF family of tumor suppressors would emerge as critical negative effectors of Ras,
with some of the members far better characterized than others.

1.3.1 – Overview of the RASSF Family:

The RASSF (Ras-Association Domain Family) proteins belong to a family of
tumor suppressor proteins that is comprised of ten members (RASSF1-10), each with
multiple splice variants, with the exception of RASSF9 and 10 (171,172) (Figure 4).
Currently, the direct association with oncogenic Ras has been observed for RASSF1A,
5A, and 6 (12,173-175). RASSF5A (NORE1A) was the first member of the RASSF
protein to be cloned (14), hence the name NORE1 for Novel Ras Effector 1. The race to
characterize the functional role of this family officially began once they were shown to
behave as tumor suppressors.
The Ras Association (RA) domain is a functional domain found in several crucial
Ras effectors, such as RalGDS and AF-6 (176). This is one of the most important
consensus binding sites for all of the RASSF family members. In addition to the RA
domain, RASSF proteins have several functional domains that regulate association with
other proteins. The Salvador-RASSF-Hippo (SARAH) domain plays a role in specific
protein-protein interactions as well as the homo- and heterodimerization of RASSF
isoforms (177). Some of the key associations of RASSF proteins via the SARAH domain
involve downstream kinases MST1 and MST2 as well as the tumor suppressor Salvador
in order to promote apoptosis (178). As a whole, these various domains allow for
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Figure 4: Schematic representation of the 10 human members of the RASSF family
of tumor suppressors. Highlighted are three functional domains: the diacylglycerol
binding (DAG) domain, the Ras Association (RA) domain, and the Salvador-RASSFHippo (SARAH) domain. These proteins do not have any apparent enzymatic activity
and are thought to primarily act as scaffolding molecules to promote the formation of
critical tumor suppressor complexes. Direct association with oncogenic Ras has only
been observed for RASSF1A, 5A (NORE1A), and 6. A majority of these tumor
suppressors are inactivated in a variety of different human cancers, primarily by promoter
methylation. Figure adapted from the Atlas of Genetics and Cytogenetics in Oncology
and Hematology.
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associations with numerous molecules and determine the involvement of RASSF proteins
in several biological pathways in order to carry out tumor suppressor functions (177).
Perhaps the most well characterized RASSF family member is RASSF1A. It was
shown in 2000 that the 3p21.3 region of the human genome contained one or more tumor
suppressors, because this region frequently suffers loss of heterozygosity in lung cancer
(179). That same year, Damman and colleagues cloned a gene in this region that they
called RASSF1 because it contained a putative RA domain (180). Differential promoter
activity and alternative splicing can lead to seven different transcripts (RASSF1A-G),
though the two major isoforms are RASSF1A and RASSF1C (180). Of note, RASSF1A
is considered a bona fide tumor suppressor, as knockout of RASSF1A in mice promotes
an enhanced rate of cancer development (181). Additional work showed that RASSF1A
is frequently inactivated by epigenetic mechanisms in human tumor cells (13,15,182).
Furthermore, RASSF1A can also contain point mutations in up to 15% of primary tumors
(183). Thus, RASSF1A may be one of the most frequently inactivated tumor suppressors
identified in human cancer to date (15).
The RASSF1A protein regulates a broad range of biological processes that are
essential for normal growth control. Lacking enzymatic activity (15), RASSF1A seems to
act as a scaffolding molecule in order to modulate tumor suppressor pathways. RASSF1A
plays a critical role in microtubule stability by interacting with several micro-tubule
associated proteins (MAPs), in turn forming a complex with microtubules and regulating
mitosis and cell cycle progression (15). One of the ways RASSF1A is thought to regulate
the cell cycle is by inhibiting the accumulation of cyclin D1 and blocking the cell cycle at
the G1/S phase (184,185). Furthermore, there is some evidence suggesting that
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RASSF1A mediated stabilization of microtubules may have a role in the regulation of
autophagy (186). RASSF1A has also clearly been implicated in promoting apoptosis by
associating with pro-apoptotic kinases MST1/2 to modulate their kinase activity, in turn
activating the HIPPO pathway and inducing cell death (178). More recently, it has been
shown that RASSF1A is also directly involved in DNA repair by regulating the
acetylation of the DNA repair protein XPA (187). This finding shows that, in addition to
acting as a scaffolding molecule, RASSF1A can also regulate protein function by
modulating their post-translational modifications. However, this function has been
defined solely for RASSF1A, the best characterized member of the family, and it remains
to be seen if the other members of the RASSF family can perform such a powerful
function. While the functions of the majority of the other RASSF family members remain
unclear, more evidence has come to light suggesting that another RASSF member may be
just as potent a tumor suppressor: RASSF5, or NORE1A.

1.3.2 – The Tumor Suppressor NORE1A (RASSF5):

NORE1 was the first member of the RASSF family of proteins to be cloned (14).
While differential promoter usage and alternative splicing mechanisms leads to the
expression of three transcripts (A-C), NORE1A is the longest and most common isoform.
NORE1A has been shown to have approximately 50% sequence homology to the
relatively well characterized RASSF1A tumor suppressor (188). As in the case with
RASSF1A, the initial evidence suggested that NORE1A behaves as a tumor suppressor.
NORE1A is frequently down-regulated in human tumors by promoter methylation, and in
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some primary tumors the NORE1A locus undergoes loss of heterozygosity (15,189). In
addition, a genetic translocation event leading to loss of NORE1A results in a familial
human cancer syndrome (18). Several in vitro studies have shown that exogenous
expression of NORE1A can promote apoptosis and in some cases cell cycle arrest
(12,17,19). Additionally, restoring endogenous levels of NORE1A expression to a
NORE1A-negative tumor cell line suppressed the tumorigenic phenotype (12). While the
evidence clearly implicates NORE1A as a tumor suppressor, how NORE1A functions in
this role remains relatively unclear.
Interestingly, NORE1A has been shown to associate with oncogenic Ras via its
RA domain in a GTP-dependent manner (19), with a similar affinity compared to that of
other known Ras effectors (190). Because NORE1A was shown to form an endogenous
complex with Ras in cells (19), NORE1A is now considered a bona fide Ras effector
(191). Since activated forms of Ras are known to paradoxically induce growth inhibitory
pathways in addition to classical growth promoting ones, it was thought that NORE1A
could behave as a critical negative effector of Ras.
One of the first mechanisms of NORE1A mediated tumor suppression
investigated was the ability of NORE1A to bind to the kinases MST1/2, key components
that feed into the HIPPO tumor suppressor pathway (192). Briefly, the core of the HIPPO
pathway consists of a kinase cascade, whereby MST1/2 phosphorylate and activate the
kinases LATS1/2, in turn phosphorylating the transcriptional co-activators YAP and TAZ
(193). Phosphorylation of YAP and TAZ will either retain them in the cytoplasm or
promote their degradation, in turn promoting the induction of apoptosis (193). Initial
work published by Avruch and colleagues suggested that Ras/NORE1A can drive

33

apoptosis by binding to MST1/2 (192). However, their findings failed to show an
increase in the kinase activity of MST1/2 as well as not showing any effects on
YAP/TAZ phosphorylation. Interestingly, a report by Aoyama et al. showed that mutants
of NORE1A lacking the MST-binding domain can inhibit tumor cell growth
independently of the MST1/2 kinases (17). Thus, the role of NORE1A in regulating the
HIPPO pathway is quite controversial, though it seems that by some currently unknown
mechanism NORE1A may modulate effectors of the HIPPO pathway, either directly via
MST1/2 or non-canonically.
Recently, work performed by Schmidt and colleagues has characterized a novel
Ras-NORE1A axis in the regulation of the Wnt pathway. They showed that NORE1A
forms a direct, endogenous, Ras-regulated complex with the E3 ubiquitin ligase β-TrCP,
ultimately promoting the degradation of the terminal executor of Wnt signaling, β-catenin
(194). β-catenin serves as both a nuclear transcriptional regulator and a key component of
adherens junctions (195). Thus, by recruiting β-TrCP and promoting the ubiquitination
and subsequent degradation of β-catenin, NORE1A can regulate the stability and turnover
of important proteins. Furthermore, the work identifies a novel Ras regulated pathway of
growth inhibition. However, Ras is known to negatively affect growth not only by
regulating apoptotic pathways, but also by promoting senescence. Once it was established
that NORE1A seemed to play a role in cell cycle arrest (191), it raised the intriguing
possibility that NORE1A could be a senescence effector of Ras.
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1.3.3 – The Link Between Ras-Induced Senescence and NORE1A:

It is widely believed that the senescence response is a crucial fail-safe mechanism
that protects the cells from tumorigenic transformation, such as aberrant Ras signaling
(196). Ras-induced senescence came to light in 1997, when it was shown to promote G1
arrest and cause an increase in the senescent proteins p53, p21, and p16 (159). While the
mechanisms are not fully defined, it is widely accepted that Ras-induced senescence
primarily involves the p53 and Rb pathways (169). The link between Ras and the
activation of these two powerful senescence pathways is still missing, though the
hypothesis remains that it must be regulating these pathways through one of its negative
effectors.
NORE1A promotes apoptosis when over-expressed or in the presence of activated
Ras, but lower, more physiological levels of NORE1A seem to promote G1 cell cycle
arrest (17). With the exception of the MST kinases, the signaling pathways involved in
NORE1A mediated tumor suppression remain poorly defined. In order to try and identify
novel mechanisms of action of NORE1A, Calvisi and colleagues performed a microarray
analysis of kidney cells induced to express NORE1A at physiological levels, and
determine alterations in gene expression by qRT-PCR. Of particular interest was the
induction of the cyclin-dependent kinase (cdk) inhibitor p21CIP1 (191). Similar to
NORE1A, over-expression of p21CIP1 induces G1 arrest (197). The study showed that
NORE1A over-expression up-regulates p21CIP1, but more importantly, loss of NORE1A
expression led to the reduction in p21CIP1 levels (191). One of the best characterized
activators of p21CIP1 is p53 (198). Interestingly, the work done by Calvisi et al. showed

35

that the activation of p21CIP1 by NORE1A is p53 dependent, and that by some unknown
mechanism, NORE1A promoted the nuclear translocation of p53 (191). This links
NORE1A to the p21CIP1/p53 pathway, suggesting that NORE1A might be involved in
Ras mediated activation of p53.
As Ras senescence pathways are known to operate, in part, via p53 (159),
Donninger et al. examined the potential role of NORE1A in Ras-induced senescence and
p53 activation. Their findings showed that NORE1A is a potent inducer of p53 dependent
senescence, and that knockdown of NORE1A impaired Ras-induced senescence and
enhanced its transforming ability (20). Specifically, NORE1A forms an endogenous, Ras
regulated complex with the kinase HIPK2, and that this interaction is essential for
Ras/NORE1A induced senescence (20). Collectively, they showed that NORE1A
positively regulates the pro-senescent post-translational modifications of p53 while also
negatively regulating its pro-apoptotic modifications, which occur as a result of Ras
mediated scaffolding of p53 and HIPK2 via NORE1A. While this work clearly implicates
NORE1A as a senescence effector of Ras by activating p53, the loss of p53 did not
completely abrogate the ability of NORE1A to induce senescence, suggesting that there
might be additional mechanisms by which NORE1A can promote senescence. In addition
to the p53 pathway, Ras can promote the induction of senescence by activating another
tumor suppressor: the retinoblastoma protein, Rb.

1.4 – The Retinoblastoma Tumor Suppressor:
The retinoblastoma susceptibility gene (Rb-1) was the first tumor suppressor to be
cloned, and was originally identified in pediatric malignant tumors of the retina known as
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retinoblastoma (199). Rb has now been identified as a crucial tumor suppressor and is
believed to be directly or indirectly inactivated in nearly all human cancers (21). The
Retinoblastoma tumor suppressor belongs to a cellular pathway that plays a crucial role
in restricting the G1-S transition of the cell cycle (200). However, it is now evident that
Rb plays multiple tumor suppressive functions in addition to its proto-typical role of cell
cycle regulation. Interestingly, Rb has been shown to bind to over one hundred protein
partners and has been shown to mediate transcriptional regulation of hundreds of target
genes. These protein partners and transcriptional targets are thought to mediate the
numerous cellular functions of Rb, including temporary and permanent cell cycle arrest,
genomic stability, and differentiation (21). For a long time, Rb has been viewed as “just”
a regulator of cell cycle progression; however, recent observations indicate that Rb
functions in multiple pathways and biological processes that are dysregulated during
tumor initiation and progression (200).

1.4.1 – The Discovery of Rb:

Retinoblastoma (Rb) is the most common intra-ocular malignant tumor in
childhood, with an incidence of 1 in 15,000 live births (201). The most important studies
to investigate the pathogenesis of retinoblastoma began with work published by Knudson
in 1971, which concluded that retinoblastoma could be inherited and formulated the
“two-hit theory” in order to explain its pathogenesis (202). He believed that the tumor
phenotype is not apparent unless both copies of the gene are damaged. The cloning of the
Rb gene and the identification of biallelic Rb mutations in retinoblastoma tumors confirm
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the hypothesis that such gene products exert the action of a tumor suppressor. Several
human tumors show mutations and deletions of the Rb gene, and inherited allelic loss of
Rb confers increased susceptibility to cancer formation (203).

1.4.2 – Rb and Cancer:

Mutations in the Rb pathway are almost universal in cancer, but different
components of this pathway are selectively affected in distinct cancer types (200).
Originally, it was shown that the Rb-1 gene is a frequent target for direct mutation only in
small cell lung carcinoma and retinoblastoma (204,205). However, multiple reports have
gone on to show that mutations affecting the retinoblastoma gene are actually frequently
encountered in other cancers, including osteosarcoma, prostate, and breast cancer (206).
As a further indication of its fundamental role in tumor suppression, Rb can be
functionally inactivated by constitutive hyperphosphorylation in tumors that do not have
mutations in the retinoblastoma gene (207). Furthermore, loss of heterozygosity at the
Rb-1 locus has been reported in many different sporadic cancers, suggesting that it is
directly mutated outside of the lung and retina, but on a less frequent basis (208). Lastly,
DNA tumor viruses that express oncoproteins, such as adenovirus E1A, SV40 large
tumor antigen, and human papillomavirus (HPV) E7, bind and inactivate Rb (209-211).
These proteins have all been shown to be required in order for the viruses to transform
cells. However, the retinoblastoma protein is most frequently inactivated in human cancer
by the negative regulatory activity of cyclin dependent kinases (212). Collectively, it is
the dysfunction of the Rb pathway that is considered to be critical for the development
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for the majority of human cancers, in large part because of the loss of functional tumor
suppressive functions of Rb.

1.4.3 – Tumor Suppressive Functions of Rb:

Since the late 1980s, it has been shown that Rb behaves as a tumor suppressor.
Over the years, the mechanisms by which Rb can promote its tumor suppressive
functions have been elucidated. It is now believed that the presence of Rb may prevent
tumor formation by inducing differentiation, controlling-cell cycle arrest, maintaining
genomic stability, and inducing senescence in response to oncogenic stresses (21).
Furthermore, the absence of Rb has been associated with increased angiogenesis (213)
and metastasis (214), although the mediators of these functions are less well understood.
While copious amounts of research has been done to characterize the mechanisms of
actions of Rb, the fundamental aspects of Rb mediated tumor suppression focus on two
critical components: regulation of the cell cycle and induction of cellular senescence.

1.4.3.1 – Rb and Cell Cycle Progression:

Two of the most important proteins involved in the cell cycle machinery are
cyclin-dependent kinases (Cdks) and cyclins. Cyclin/Cdk complexes are formed during
distinct phases of the cell cycle, and are specifically involved in the phosphorylation of a
distinct set of target proteins, including Rb. The fluctuation in cyclin expression and the
resultant oscillation in Cdk activity forms the basis of a coordinated cell cycle

39

progression. Cdks activated in response to mitogenic stimuli phosphorylate and inactivate
Rb, allowing for progression through the cell-cycle (215).
One of the critical steps in cell cycle progression is the G1 to S transition phase.
At this particular point, the cell may decide whether to continue its advance and complete
the cell cycle. This point is referred to as the “restriction point,” or the R point, and is
thought to be a critical event in normal cellular proliferation control (216). It is perceived
that Rb is the key mediator that serves as the R point switch. Rb is hypophosphorylated in
resting G0 cells, is increasingly phosphorylated during progression through G1 and is
maintained in a hyperphosphorylated state until late mitosis (217-219).
When in its actively growth-suppressing hypophosphorylated state, Rb physically
associates with E2F factors and blocks their ability to activate expression of genes that
encode products necessary for S-phase progression (Figure 5). The Rb proteins repress
gene transcription required for transition from G1 to S phase by directly binding to the
trans-activation domain of E2F and by binding to the promoter of these genes as a
complex with E2F (220). The importance of the Rb-E2F interaction in cell growth control
is demonstrated by the finding that all naturally occurring Rb mutants isolated from
human tumors lack the ability to bind and negatively regulate E2F (221). However, Rb
can regulate G1-S transition through E2F independent mechanisms. Rb has been shown
to inhibit Cdk activity and G1-S progression by increasing the expression of p27;
furthermore, Rb can stabilize the p27 protein by binding the Skp2 protein and interfering
with the Skp2-p27 complex, thus avoiding p27 ubiquitination (222).
In addition to directly binding and blocking the activation of E2F transcription
factors, Rb can repress transcription by remodeling chromatin structure through its
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Figure 5: A model for cell cycle regulation by Rb. The Rb tumor suppressor is
primarily regulated by its phosphorylation status. When Rb is hypophosphorylated, it will
bind to and inhibit the activity of E2F transcription factors, as well as recruit chromatin
modifying enzymes to repress the transcription of E2F responsive genes. However,
cyclin/Cdk complexes can be activated in response to mitogenic stimuli and can
phosphorylate and inactivate Rb, allowing for progression through the cell cycle. While
the mechanisms involved in Rb phosphorylation are well characterized, the activation of
Rb by dephosphorylation remains poorly defined.
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interaction with proteins such as hBRM, BRG1, HDAC1, and SUV39H1 (223) which are
involved in nucleosome remodeling, histone acetylation/deacetylation, and methylation,
respectively. Of particular interest is the ability of Rb to recruit HDAC1 to E2F
complexes to repress gene expression, such as cyclin E (224). Work done by Zhang et al
in 2000 showed that histone deacetylase is involved in modulating the repressive activity
of Rb on E2F gene promoters (225). In conclusion, Rb has now been shown to have
multiple mechanisms involving the regulation of cell cycle. Interestingly, prolonged cellcycle arrest can lead to the induction of senescence.

1.4.3.2 – Rb and Senescence:

Multiple reports have shown that Rb is required for oncogene induced senescence
in mouse cells (226,227), and it is widely believed that Rb can induce the senescence
phenotype in part by promoting a permanent cell cycle arrest. However, in human cells
both the p53 and the Rb pathways have to be inactivated in order for Ras to bypass
senescence (159), suggesting that both pathways are required in human systems. These
differences in the senescence mechanism may provide a logical explanation as to why it
is easier to transform rodent cells than human cells in experimental systems (228). While
it is clear that Rb is required for Ras-induced senescence, the mechanisms linking Ras to
the Rb pathway remain unknown.
One mechanism by which Rb can promote this irreversible cell cycle arrest is by
promoting the formation of heterochromatin around genes required for cell proliferation,
such as E2F target genes. Such heterochromatin structures are referred to as SAHF
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(senescence-associated heterochromatin foci). While these structures are critical for the
induction of senescence, it does not explain how Rb is activated to promote such a
phenotype. In addition, work performed by Chicas and colleagues showed that, in
addition to E2F repression, Rb can repress the replication machinery of senescent cells in
part by repressing the expression of cyclin E1 (215).
During Ras-induced senescence, Rb can be activated by the cyclin-dependent
kinase inhibitors (CKIs) which block the Cdks that normally inactivate the Rb protein by
phosphorylation (229). Two of the most important CKIs are p21 and p16, both of which
are simultaneously required for Ras-induced senescence in human cells (230).
Interestingly, inhibition of Cdks is not the only means to inhibit Rb phosphorylation.
While the mechanisms that lead to the phosphorylation of Rb are well documented, the
knowledge of the process that counteracts Rb phosphorylation is still quite limited (231).
Recent work has now shown that two phosphatases, PP1 and PP2, play pleotropoic roles
in the mammalian cell cycle, particularly in mitosis. Further support for a major role for
PP1 in Rb dephosphorylation came from a yeast two-hybrid screen that reported a direct
association between Rb and the catalytic subunit of PP1. It was later shown through in
vitro binding assays that isoform PP1A preferentially binds the hypophosphorylated form
of Rb and that this association occurs in early G1. It must be noted that subsequent work
showed that Rb actually binds all PP1 isoforms, but that PP1A is widely considered to be
one of the major cellular phosphatases involved in Rb dephosphorylation (232-236).
Interestingly, it has been recently reported that PP1A enzymatic activity is regulated by
Ras (237) and additional reports have shown a correlation between Ras activation and
PP1/PP2A activation (238). More importantly, work performed by Castro and colleagues
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showed that PP1A could behave as a tumor suppressor in human cells through its
contribution to Ras-induced senescence (22). This highlights the importance of Rb
activation by dephosphorylation in order to promote Ras-induced senescence. However,
the mechanism by which Ras regulates PP1A remains unknown.

1.5 – A Novel Signaling Pathway for NORE1A Induced Senescence:

Increasing evidence has implicated Ras-induced senescence as a potent barrier
against malignant transformation, and it is widely believed that loss of functional
senescence pathways allows Ras to bypass senescence induction and drive
transformation. The exact mechanisms by which Ras induces senescence are not fully
understood, but center around two powerful senescence effectors: p53 and Rb. Ras has
been shown to promote senescence by activating both of these tumor suppressors. And
while p53 and Rb are required to promote Ras-induced senescence, the mechanisms
linking Ras to p53 and Rb remain unknown.
Recently, NORE1A has been identified as a bona fide tumor suppressor, and has
now been shown to be a negative effector of Ras. While initial findings depicted a novel
role for NORE1A as a mediator of Ras-induced apoptosis, the work revolved around
artificial, over-expression studies, and thus may have masked the true tumor suppressive
functions of NORE1A. In 2009, work performed using more physiological levels of
NORE1A expression strongly suggested that NORE1A may be far more important in cell
cycle arrest, bringing up the intriguing possibility that NORE1A might be playing a role
in oncogene induced senescence. Recent work has now clearly implicated NORE1A as a
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direct, potent senescence effector of Ras. These groundbreaking findings by Donninger et
al. highlight that NORE1A promotes Ras-induced senescence by scaffolding HIPK2 to
p53 in a Ras dependent manner, in turn modulating the pro-senescent post-translational
modifications of p53. Although NORE1A acts through p53 to promote senescence, some
of the pro-senescent phenotype of NORE1A still remains even after all p53 has been
removed. This suggests that NORE1A induced senescence may not be promoted
exclusively by p53, pointing to the possibility that NORE1A may have additional,
previously unidentified mechanisms to activate Ras-induced senescence. Bearing in mind
that the onset of senescence in human cells requires both p53 and Rb, we hypothesized
that NORE1A might also act through the Rb pathway. Furthermore, PP1A was detected
in complex with NORE1A in a yeast two-hybrid screen (23), suggesting that these two
proteins may interact and potentially provide the missing link that allows Ras to regulate
Rb in order to promote senescence.
Work presented in this dissertation demonstrates a novel mechanism, in addition
to p53, by which NORE1A can promote senescence induction. We will show evidence
that NORE1A can activate the powerful Rb tumor suppressor. Through the formation of
an endogenous, Ras regulated complex with the phosphatase PP1A, NORE1A can
scaffold PP1A onto Rb in turn promoting its dephosphorylation, a pro-senescent event.
Additionally, we show that NORE1A requires Rb to promote senescence in mouse
embryonic fibroblasts, and that loss of Rb significantly suppresses NORE1A induced
senescence in human cells. These findings explain why NORE1A is such a powerful
tumor suppressor. Collectively, NORE1A seems to behave as a critical senescence
effector of Ras, by linking Ras to both the p53 and Rb pathways to fully promote the
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senescent phenotype. In addition to regulating Rb dephosphorylation, we also provide
evidence that NORE1A can regulate some of the non-phosphorylation post-translational
modifications of Rb, including the acetylation and the SUMOylation, both of which are
currently believed to activate the tumor suppressive phenotype of Rb.
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CHAPTER 2

MATERIALS AND METHODS

2.1 – Vectors and Plasmids:

pCDNA3-HA and pCDNA3-FLAG – pCDNA3 expression plasmid vector was purchased
from Invitrogen (Carlsbad, CA). It contains a CMV promoter upstream of a multiple
cloning site; however, it does not express an epitope tag, making it inconvenient for basic
biological studies. Therefore, we generated pCDNA3 expression vectors containing fused
HA and FLAG epitope tags, which were performed by Dr. Geoffrey Clark. Ultimately,
the expression of inserted genes results in either a fused HA of FLAG tag on the Nterminus of the protein.

pEGFP-C1 – This vector construct was purchased from Clontech (Mountain View, CA).
It is driven by a CMV promoter and allows for a Green Fluorescent Protein (GFP) tag to
be fused to cDNAs that can be inserted into the multiple cloning site. This is a very useful
tool that can be used to track protein localization within the cell by fluorescent
microscopy as well as for protein-protein interactions via coimmunoprecipitations
(described in Section 2.8.1).

47

pmKATE2-C – This vector construct was obtained from Evrogen (Moscow, Russia).
Nearly identical to pEGFP-C1, this construct expresses a Red Fluorescent Protein (RFP)
tag that can be fused to cDNAs inserted into the multiple cloning site, an can be used in a
similar manner for biological assays.

NORE1A – NORE1A is the centerpiece of this dissertation project. The full length human
NORE1A was purchased from Origene (Rockville, MD) and was sub-cloned into the
relevant expression constructs by Dr. M. Lee Schmidt. Briefly, the NORE1A cDNA
clone was PCR amplified with primers “hNore1a5” with the sequence 5’ –
GCAGATCTATGGCCATG GCGTCCCCGGCCATC – 3’ and “hNore1a3’” with the
sequence 5’ – GCGAATTCTTACCCA GGTTTGCCCTGGGATTC – 3’ to yield a 1273
base pair DNA fragment with 5’-BglII and 3’-EcoRI restriction sites. The fragment was
TOPO cloned into pCR2.1-TOPO for sequencing and sub-cloning applications. Postanalytical confirmation, the pCR2.1-TOPO-NORE1A plasmid was digested with BglII
and EcoRI and ligated into a BamHI/EcoRI digest of a pCDNA3 mammalian expression
construct containing an in-frame 5’-HA tag and a pCDNA3 construct containing an inframe 5’-Flag epitope tag. The BglII/EcoRI digested NORE1A fragment was also ligated
into both GFP (pEGFP-C1) and KATE (pmKATE2-C) digested with BglII and EcoRI.

H-Ras-12V and K-Ras-12V – pCGN-HA-H-Ras12v was created by cloning the fulllength H-Ras12v cDNA as a BamHI fragment into pCGN vector under the control of a
CMV promoter (239). KATE-tagged H- and K-Ras12V were generated by subcloning a
BamHI fragment from pCGN-H- and K-Ras12V into pmKATE2-C.
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shNORE1A – shRNAs for human NORE1A (#1: 5′-TATATATAGCTATATGCCT-3′;
#2: 5′-AGCTTTGTGCTAAAGGAGA-3′; Scrambled: 5′ATCTCGCTTGGGCGAGAGT
AAG-3′; RHS4531-EG83593) were obtained from Open Biosystems (Rockford, IL) (20).

shRb – pLKO-Rb1-shRNA-19 and 63 were purchased from Addgene (Plasmid #25640
and 25641). Briefly, unique short hairpin RNAs (shRNA) to the RB1 mRNA in the
pLKO.1-Puro lentiviral expression vector were obtained from Open Biosystems. Clones
19 and 63 were originally shown to have >99% knockdown of Rb expression relative to
the empty pLKO.1-infected clone (240).

siPP1A – Control (sc-37007) and siPP1A siRNA (sc-36299) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). While the sequences for the siPP1A siRNA
constructs were not disclosed by Santa Cruz, it is noted that this PP1A siRNA is a pool of
three target-specific 19-25 nucleotide siRNAs designed to knock down the gene
expression of human PP1A.

Rb – Human Rb expression construct (pGS5L-HA-Rb) was obtained from Addgene
(Plasmid #10720) and digested with BamHI/NheI and NheI/EcoRI in two separate
digests to generate 1.9 Kb and 0.8 Kb fragments, respectively. The two fragments were
cloned into pEGFP-C1 (Clontech) digested with BglII/EcoR1 to generate a GFP-tagged
full length Rb expression construct. To maintain consistency of plasmid backbones, an
identical double digest was performed in order to generate a pcDNA3.1-HA-Rb
construct. Briefly, following a double digest of pGS5L-HA-Rb to generate the 1.9 Kb and
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0.8 Kb fragments, we set up a ligation using both fragments along with a pcDNA3.1-HA
fragment from HA-XpA-2KQ that had been digested BamHI/EcoRI.

Ubiquitin – We obtained the full length, wild-type HA-tagged Ubiquitin expression
construct, pRK5-HA-Ubiquitin-WT, from Addgene (Plasmid #17608).

PP1A – We purchased the full length, wild-type GFP-tagged PP1A expression construct,
pEGFP(C1)-PP1A, from Addgene (Plasmid #44224).

SUMO1 – We purchased the full length, wild-type HA-tagged SUMO1 expression
construct, pcDNA3-HA-SUMO1-WT, from Addgene (Plasmid #48966).

PCAF – We obtained the full length, wild-type FLAG-tagged PCAF expression
construct, pCI-FLAG-PCAF, from Addgene (Plasmid #8941).

Pc2 – pEGFP-Pc2 (wild-type) was generously provided by Dr. Andrew Sharrocks, from
the University of Manchester (Manchester, United Kingdom).

IL-6-PROM-01-Luc – A luciferase reporter construct containing an IL-6 promoter was
purchased from Active Motif (Carlsbad, CA).
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2.2 – Antibodies:

Anti-GFP – The primary antibody detecting the GFP-epitope tag was purchased from
Santa Cruz Biotechnology (sc-9996). For western blot analysis and the detection of
proteins containing a GFP tag, the GFP-antibody was diluted at 1:500 in a 5% milk
solution of 1X TBST (TBS-Tween: 50mM Tris-HCl, pH 7.4, 150mM NaCl, 0.1%
Tween-20). The blots were incubated in antibody solution at 4°C overnight. After
incubation with primary antibody, blots were exposed to a mouse-IgG-HRP secondary
(Cat. # NA931-1ML) purchased from Amersham (acquired by GE Healthcare, Uppsala
U.K.) at a dilution of 1:10,000 in 1X TBST for 1 hour at room temperature, followed by
detection by West Pico Enhanced Chemi-Luminescence purchased from Thermo Fisher
Scientific (Rockford, IL).

Anti-HA – The primary antibody detecting the HA-epitope tag (Cat# MMS-101P) was
purchased from Covance Inc. (Princeton, NJ). For detection of HA-tagged proteins on a
western blot, the antibody was generally diluted at 1:10,000 in a 5% milk solution of 1X
TBST. However, for particular instances such as detections of weaker protein-protein
interactions, the HA primary antibody was used at a dilution of 1:5,000. Blots were
incubated in primary antibody solutions overnight at 4°C. Following the primary
antibody incubation, western blots were exposed to a mouse-IgG-HRP secondary at a
dilution of 1:10,000 in 1X TBST for 1 hour at room temperature, and ultimately detected
by West Pico ECL.
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Anti-FLAG – The primary antibody used for detection of proteins with FLAG epitope
tags was purchase from Sigma (Cat# F1804). The antibody was diluted at 1:1,000 in a
5% milk solution of 1X TBST solution, and blots were incubated overnight at 4°C. After
the incubation with primary antibody, blots were exposed to a mouse-IgG-HRP
secondary antibody at a dilution of 1:10,000 in 1X TBST for 1 hour at room temperature
and detected by West Pico ECL.

Anti-tRFP – The primary antibody used for detecting the KATE epitope tag was
purchased from Evrogen (Cat#AB233). While this primary antibody is generated to
detect the RFP tag, it is also able to detect the mKate2 tag, allowing it to be effective for
our studies. Western blots were incubated in the anti-RFP antibody at a dilution of
1:1,000 in a 5% BSA (bovine serum albumin) (Sigma Cat. #A3059-100G) solution in 1X
TBST solution at 4°C overnight. Following incubation in primary antibody, blots were
exposed to a Goat anti-Rabbit-HRP secondary antibody from KPL Inc. (Gaithersburg,
MD) (Cat. #374-1506) at a dilution of 1:10,000 in 1X TBST for 1 hour at room
temperature, and detected using West Pico ECL.

Anti-NORE1A - Rabbit polyclonal NORE1A antibodies were raised against the synthetic
human NORE1A peptide: KYDKFRQKLEEALRESQGKPG by ProSci (Poway, CA).
Two different rabbit polyclonal antibodies were generated by ProSci: PAS #17071
(0.73mg/mLx2.75mL=2.0mg) and PAS #17072 (1.17mg/mLx2.0mL=2.34mg), both in
PBS with 0.02% NaN3. The date of generation was October 3rd, 2014. These antibodies
were used for detection of NORE1A on western blots and also for immunoprecipitations
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(IP). After performing test IPs using over-expression studies, we concluded that PAS
#17071 was better suited for IPs, and PAS #17072 would be used for western blot
analysis. For IPs, whole cell lysates were incubated with 10 µL (equaling approximately
7.3 µg) of PAS #17071 antibody in 1 mL final volume of modified RIPA buffer
overnight, following by a 4 hour immunoprecipitation using rabbit conjugated agarose
beads purchased from eBiosciences Inc. (acquired by Rockland Inc., Pottstown PA) (Cat.
#00-8800-25). For full IP protocol, see Section 2.8.1.2) – immunoprecipitations. For
western blot analysis, the PAS #17072 antibody was added to a 5% milk in 1XTBST
solution at a dilution of 1:500 and incubated at 4°C overnight. The blots were then
probed with a Rabbit-IgG-HRP (KPL) secondary antibody at a dilution of 1:10,000 in 1X
TBST for 1 hour at room temperature, followed by detection using a West Pico ECL.

Anti-Phospho-Rb-Ser795 – When western blotting for phosphorylated levels of
endogenous Rb protein, an anti-Rb antibody that specifically recognized phosphorylated
Rb at Serine 795 was purchase from Cell Signaling Technology (Beverly, MA) (Cat.
#9301). This antibody was diluted at 1:1,000 in a 5% BSA/1XTBST solution and blots
were incubated overnight at 4°C. Following incubation in primary antibody, blots were
exposed to a goat anti-Rabbit-HRP secondary antibody at a dilution of 1:10,000 in
1XTBST solution for 1 hour at room temperature, followed by detection of protein using
West Pico ECL.

Anti-Rb [4H1] – Endogenous levels of total Rb protein was detected on a western blot
using an antibody purchased from Cell Signaling (Cat. #9309) diluted at a concentration
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of 1:1,000 in 5% milk in 1X TBST. Blots were incubated in primary antibody at 4°C
overnight. Following the primary antibody incubation, blots were probed with a mouseIgG-HRP secondary antibody diluted at 1:10,000 in 1X TBST solution for 1 hour at room
temperature, followed by detection using West Pico ECL.

Anti-PP1A – When western blotting for endogenous levels of PP1A protein, an antiPP1A antibody (C-19) purchased from Santa Cruz (sc-6104), and is a goat polyclonal
IgG provided at 200 µg/mL, and its epitope maps at the C-terminus of PP1A of human
origin. This antibody was diluted at 1:200 in a 5% milk in 1X TBST solution; blots were
incubated in PP1A primary antibody overnight at 4°C. Following the overnight
incubation, blots were probed with a rabbit anti-Goat IgG-HRP (purchased from Santa
Cruz, sc-2768) diluted at 1:10,000 in 5% milk in 1X TBST solution for 1 hour at room
temperatures, followed by protein detection using West Pico ECL.

Mouse and Rabbit-HRP TrueBlot Secondary Antibody – Instances occurred when
experiments required agarose conjugated beads that are bound with mouse or rabbit
secondary antibodies. This can cause the heavy and light chains of antibodies to be
detected by the respective mouse/rabbit secondary antibodies during western blot
analysis. Fortunately, a TrueBlot® product line of secondary antibodies generated by
Rockland Inc. do not detect heavy and light chain IgG bands. Thus, there were some
cases were this secondary antibody was used rather than the standard mouse-HRP
secondary antibody previously mentioned. Western blots were incubated with the
TrueBlot Mouse antibody (Cat. #18-8817-33) was diluted at a dilution of 1:2,000 in a 5%
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milk in 1X TBST solution for approximately 1 hour, followed by detection using West
Pico ECL. Similarly, the TrueBlot Rabbit-HRP secondary antibody does not detect the
heavy and light chains of antibodies conjugated to agarose beads. When necessary, the
TrueBlot Rabbit secondary (Cat. #18-8814-33) was used in exactly the same manner as
the TrueBlot Mouse secondary antibody.

2.3 – Cell Lines:

HEK 293 – Human Embryonic Kidney 293 cells (HEK 293) are a specific cell line
originally derived from human embryonic kidney cells. These embryonic kidney cells
were transformed by exposing cells to sheared fragments of adenovirus type 5 DNA
(241). HEK 293 cells are straightforward to grow in culture, but more importantly
transfect very readily and have been widely used in cell biology as hosts for gene
expression. These cells were purchased from ATCC (Manassas, VA) and were widely
used for our studies. HEK 293 cells are grown in DMEM supplemented with 10% FBS.

HEK 293T – An important variant of the HEK 293 cell line is the HEK-293T cell line,
which have been modified to express the SV40 Large T-antigen, which allows for
increased protein production by allowing replication of transfected plasmids containing
the SV40 origin of replication. This cell line was primarily used for coimmunoprecipitation experiments. This cell line was also obtained from ATCC and are cultured
in DMEM supplemented with 10% FBS.
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COS-7 – The COS-7 cell line (an abbreviation for CV-1 in Origin with SV40 genes) is a
fibroblast-like cell line derived from the kidney cells of the African green monkey
(Cercopithecus aethiops). COS-7 cells were developed by Yakov Gluzman by
immortalizing CV-1 cells with a mutant version of the SV40 virus that can produce the
Large-T antigen but has a defect in genomic replication (242). While not being human in
origin, COS-7 cells are a valuable tool to study potential co-localization of fluorescently
labeled proteins, as their flat morphology allow the option to do high resolution, live-cell
imaging microscopy as it reduces background fluorescence. This cell line was purchased
from ATCC and is maintained in DMEM supplemented with 10% FBS.

A549 – Purchased from ATCC, A549s are human lung adenocarcinoma epithelial cells.
This cell line was initiated by D.J. Giard and colleagues through explants culture of lung
carcinomatous tissue from a 58-year old Caucasian male (derivation information courtesy
of ATCC). This cell line harbors the K-Ras (G12S) mutation, giving these cells a
constitutively activated Ras protein. In addition, these cells are null for NORE1A
expression, and it has been recently shown that expressing NORE1A in A549 cells leads
to the induction of cellular senescence (20). A549s also express wild-type p53 and Rb.
These cells were cultured in DMEM supplemented with 10% FBS.

NCI-H1299 – This cell line, obtained from ATCC, is a human non-small cell lung
carcinoma derived from the lymph node. There are two significant reasons why these
cells are so highly transformed. First, H1299 cells have a point mutation in N-Ras (NRas-Q61K), rendering it constitutively active. Second, they do not express p53 (243) as a
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result of a homozygous partial deletion within the p53 gene. These cells are cultured in
RPMI medium supplemented with 10% FBS.

HBEC-3KT – This is an immortalized, non-transformed human bronchial epithelial cell
line, which was provided courtesy of Jerry Shay (UT South Western, Dallas, TX). This
cell line was established by infecting primary human bronchial epithelial cell culture with
human telomerase (hTERT) and mouse cyclin dependent kinase 4 (CDK4) expressing
retrovirus constructs and selecting with Puromycin and G418 (244). Because they were
immortalized without the use of any viral oncogenes, such cells can almost be considered
primary cells. These cells were cultured in keratinocyte serum-free medium containing
bovine pituitary extract and recombinant epidermal growth factor (Invitrogen).

HepG2 – This is a human hepatocellular carcinoma cell line derived from the liver tissue
of a 15-year old Caucasian male who had well-differentiated hepatocellular carcinoma,
which is the fifth most common cancer worldwide. HepG2 cells contain a mutant Ras (NRas-Q61L) but have wild-type p53 and Rb (245). More importantly, NORE1A and PP1A
protein can be detected in this cell line via western blot analysis, which is the
predominant reason for which we performed endogenous coimmunoprecipitations in this
cell line. HepG2 cells are maintained in DMEM supplemented with 10% FBS.

MEFs – Mouse embryonic fibroblasts (MEFs) are primary murine cells with the
senescence machinery intact that can be isolated from mouse embryos and can be
expanded in culture. Interestingly, such cells undergo significant induction of senescence
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in the presence of activated Ras, making these cells useful tools to study Ras effectors
and their role in senescence. Wild-type and Rb-/- MEFs were generously provided by Dr.
Brian Clem (University of Louisville, Louisville, KY) and were used to study the
potential role of Rb in NORE1A mediated senescence. Rb-/- MEFs were generated and
validated as previously described (226). MEFs were grown in DMEM supplemented with
10% FBS.

293FT – The 293FT cell line is a fast-growing, highly transfectable clonal isolate derived
from human embryonic kidney cells transformed with the SV40 large T antigen. The
293FT cell line is ideal for generating high-titer lentivirus production. This cell line was
used to generate lentivirus carrying shRNAs against Rb in order to address the role of Rb
in NORE1A mediated senescence. A detailed explanation of the generation of lentiviral
particles is discussed in section 2.7.3. 293FT cells were grown in DMEM supplemented
with 10% FBS, 1% Pen-Strep, 0.1mM MEM non-essential amino acids, 6mM LGlutamine, 1mM MEM sodium pyruvate and 500g/ml G418 sulfate (Corning Cellgro
Cat. #30-234-CR).

2.4 – Cell Culture Materials:

Growth Media – Different cell lines grow optimally under different conditions, including
the growth medium. Thus, several specific growth media were obtained. Dulbecco’s
Modified Eagle’s Medium (DMEM) was purchased from Corning Cellgro (Cat. #10-013CV) and is composed of 4.5g/L glucose and supplemented with L-glutamine and
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pyruvate. The DMEM was further supplemented with 10% FBS (Valley Biomedical) and
a 1% solution of Penicillin/Streptomycin antibiotic (Corning Cellgro Cat. #30-002-CI).
RPMI 1640 cell culture medium was purchased from Corning Cellgro (Cat. #10-040-CV)
with L-glutamine. This medium was further supplemented with 10% FBS (Valley
Biomedical) and 1% Pen-Strep Antibiotic (Corning Cellgro). HBEC-3KT cells require a
special growth media formulation and we purchased this medium designed for
keratinocytes from Invitrogen (Cat. #17005-042). This kit contains Keratinocyte-SFM
medium (Cat. #10724-011) which was supplemented with provided supplements 25mg
Bovine Pituitary Extract (BPE) (Cat. #13028-014), 2.5μg human recombinant EGF (Cat#
10450-013), and 1% Pen-Strep Antibiotic (Corning Cellgro).

Trypsin – Trypsin EDTA (0.25%) was purchased from Corning Cellgro (Cat. #25-053CI) and used to remove adherent cells from culture dishes and flasks. Media was
removed by aspiration from cell culture dishes and washed once with 1X PBS, which was
purchased from Corning Cellgro (Cat. #21-040-CV and #46-013-CM). The PBS was then
aspirated and the trypsin-EDTA solution was then added, covering the bottom of the dish
with a thin layer of solution. The dishes were then placed back into the incubator for 3-5
minutes allowing the trypsin to remove adherent cells. After the cells were removed from
the flask, the trypsin-EDTA was neutralized with supplemented culture medium and the
cells were pelleted by centrifugation (5 minutes at 1500 RPM). The cell pellets were
resuspended in culture medium and plated as the application required.
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Cell Culture Flasks and Dishes – All cells were passaged in either T-25 or T-75 culture
flasks purchased from TPP. When plating cells for biological experiments, cells were
plated in 60 mm or 100mm cell culture dishes as well as 6, 12, and 24 well plates, all of
which were purchased from Greiner Bio-One. In particular instances, 96-well plates were
purchased from TPP.

Lysis Buffer and Chemicals for Cell Treatment – For biological assays where proteinprotein interactions were not involved, we lysed cells in RIPA buffer purchased from
Sigma (Cat. #R0278), which contains the following: 150mM NaCl, 1.0%, 1.0%
IGEPAL® CA630, 0.5% sodium deoxycholate, 0.1% SDS, and 50mM Tris pH 8.0. This
lysis buffer allows for efficient cell lysis and is suitable for protein detection by western
blot analysis. To inhibit the proteasome, cells can be treated with a chemical called MG132, which we obtained from Sigma (Cat. #C2211-5MG). Stock solutions of MG-132
were dissolved in DMSO to a concentration of 10 mM and diluted in cell culture media to
obtain a final working concentration of 10 µM. For the purposes of our studies, cells were
treated with MG-132 for 6 hours prior to lysis when applicable. To study changes in
protein stability, we purchased a chemical called cycloheximide from Sigma (Cat.
#P8833-10MG). It works by inactivating the transferase II enzyme involved in peptide
chain elongation, ultimately inhibiting protein synthesis. One can then analyze protein
decay over a time course to determine the stability of a protein of interest. Stock powder
of cycloheximide was dissolved in 100% ethanol (EtOH) to a concentration of 20
mg/mL, and was then added to cell culture media to obtain a final concentration of 20
µg/mL.
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2.5 – Transfections:

Transfection of DNA plasmids and siRNAs into mammalian cells is a critical
means by which to study gene function. There are multiple options that are commercially
available to transfect cells; however, different cell lines can be transfected more or less
optimally depending on the transfection reagent. Therefore, we used several different
reagents in order to transfect cells as efficiently as possible. These include: JetPRIME,
Lipofectamine 3000, and DharmaFECT.

2.5.1 - JetPRIME™ Transfection:

The JetPRIME™ DNA transfection reagent (VWR Cat# 89137-972) can be
purchased from Polyplus-Transfection Inc. (Illkirch, France). It is generally described as
a cationic polymer-based reagent to ensure high DNA transfection efficiency by forming
positively charged complexes with DNA that can enter the cell via endocytosis, in turn
releasing plasmid DNA into the cytoplasm, eventually reaching the nucleus. For most of
our transfection procedures, 1-2 µg of DNA plasmids of choice were mixed in 200 µL of
JetPRIME™ transfection buffer provided by the manufacturer. To this mix, 2-4 µL of
JetPRIME™ was added, depending on the amount of DNA (JetPRIME™ was
consistently added at a ratio of 2 µL per 1µg DNA plasmid). The mix would be vortexed
for 10 seconds and spun down for 10 seconds using a tale-top micro-centrifuge. The
DNA/JetPRIME™ mixture was incubated for 10 minutes at room temperature and was
added dropwise to the dish (in this case, 60 mm dish) and incubated for 6 to 8 hours.
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After this incubation, the culture media/transfection mix you be aspirated and fresh media
would be added and remain overnight. This general transfection protocol can be modified
based on the size of the cell culture dish used as well as the overall amount of DNA
plasmid desired. This transfection reagent was used for transfections of HEK 293, HEK293T and COS-7 cells, and would generally yield high transfection efficiency. However,
this reagent was not as efficient for transfecting other cells used in this project, such as
A549 cells.

2.5.2 – Lipofectamine 3000®:

The Lipofectamine 3000® reagent was purchased from Invitrogen (Cat.
#LC3000015). It is a lipid based formulation designed for cells that are difficult to
transfect when using other transfection reagents such as JetPRIME™. For the purposes of
this project, MEFs and A549 cells were transfected using Lipofectamine 3000®
according to the manufacturer’s instructions. Cells were plated in 35mm dishes or 12well plates (in duplicate) and thus were transfected in a similar manner. First, two tubes,
(name?) each containing 100 µL of Opti-MEM (Invitrogen Cat. #31985062), were
prepared. In the first tube, 3.75 µl per µg of DNA was added. In the second tube, the
respective DNA was added, followed by the addition of 2 µL of P3000™ reagent per 1
µg of DNA. After mixing both tubes thoroughly, the DNA/P3000™/Opti-MEM mixture
from tube 2 was added to tube 1 (containing Lipofectamine 3000®/Opti-MEM), further
mixed and incubated for 5 minutes at room temperature. After the incubation, the mixture
was added drop-wise to the cells and was incubated for 24 hours. Fresh media would be
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added to the cells the following day and were incubated for an additional 24-48 hours
depending on the biological assay being performed.

2.5.3 - DharmaFECT™ siRNA Transfection:

Transfection of siRNA into cultured mammalian cells required very specific
transfection reagents. We purchased the DharmaFECT™ transfection reagent from GE
Healthcare. All siRNA transfections of siPP1A into A549 cells were performed using this
reagent, and were always performed the day prior to transfections of DNA plasmids.
First, A549 cells were plated in 35mm dishes at a concentration of 200,000 cells per dish.
The next day, the siRNA transfection was performed according to the manufacturer’s
protocol. In tube 1, we diluted the siRNA by adding 5 µL of a 10 mM stock siRNA into
195 µL of Opti-MEM. In tube 2, we added 5 µL of DharmaFECT reagent (formulation
#2) into 195 µL of Opti-MEM. We gently mixed both tubes and allowed them to incubate
at room temperature for 5 minutes. Then, we added the contents of Tube 1 to Tube 2, for
a total volume of 400 µL. We again mixed carefully and incubated for 20 minutes at
room temperature. Following the incubation, we added 1.6 mL of antibiotic-free DMEM
to the mix for a final volume of 2 mL transfection media and a final siRNA concentration
of 25 nM. The transfection media was added dropwise to the cells and incubated for 24
hours. For optimal knockdown, fresh media would be added the following day and the
incubation was continued for a minimum of an additional 48 hours, allowing for a total of
72 hours for proper protein knockdown.
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2.6 – Molecular Biology:

In order to thoroughly address the goals involved in this project, numerous
experiments were performed which required a number of different plasmids in several
combinations. Thus, when identifying the functions of specific proteins, as well as effects
of proteins on other protein-protein interactions, it was critical that our over-expression
studies have proteins with different epitope tags. In order to address this, a number of
molecular biology techniques were performed which include the following: restriction
enzyme digests, DNA ligations, agarose gel electrophoresis, bacterial transformations,
and plasmid preparation and purification.

2.6.1 – Restriction Enzyme Digests:

In order to generate DNA plasmids with different epitope tags, plasmids of
interest must be subcloned into different expression vectors. In turn, all DNA subcloning
requires restriction enzymes to shuttle DNA fragments from one vector to another. All of
the enzymes used in this project were purchased from New England Biolabs® Inc.
(Ipswich, MA). When performing restriction enzyme digests, reactions would consist of
our DNA of interest, enzymes with their optimal buffers, and BSA when necessary.
Restriction enzyme digests were incubated for approximately 2 hours in a 37°C water
bath.
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2.6.2 – Agarose Gel Electrophoresis:

DNA from restriction enzyme digests were run on 1% agarose gels in order to
separate our linearized fragments of interested according to size. Agarose gels were made
by adding 0.5 grams of SeaKem LE agarose, purchased from Lonza (Basel, Switzerland)
(Cat. #50004), into 50 mL of 1X TAE buffer (Tris-Base, Acetic Acid, EDTA) purchased
from MediaTech (a Corning subsidiary) (Cat. #46-010-CM), giving a final concentration
of 1% gel by weight. In order to make the gel, the agarose/TAE solution had to be
melted. After melting, but before casting, 2 µL of ethidium bromide (Invitrogen) was
added and mixed well. The ethidium bromide will then intercalate into our linear DNA
allowing for the visualization of DNA using a UV box. Gels were then loaded and ran at
approximately 85 volts to allow for separation of the relevant DNA fragments. In the
instance where DNA fragments needed to be re-annealed to other vectors via DNA
ligations, the retrieval of DNA from the agarose gel was required. In such cases, DNA
bands were cut out and purified using a GenElute™ column (purchased from Sigma, Cat.
#56500) according to the manufacturer’s protocol.

2.6.3 – DNA Ligation:

Following restriction enzyme digests, agarose gel electrophoresis and DNA
purification, DNA ligation reactions were performed in order to recombine DNA
fragments into our vectors of interest. Generally, a 3:1 molar ratio of vector backbone
fragment to the DNA fragment containing our gene of interest was used in order to
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achieve efficient ligations. The two DNA fragments (though the double digest of human
Rb contained three fragments) were added to eppendorf tubes along with 1µL of 10X
ligation buffer, 1 µL of T4 DNA ligase enzyme (both buffer and ligase were purchase
from New England Biolabs®), and 5 µL of molecular grade water were added, making a
total ligation mixture volume of 10µL. The ligation reaction was mixed thoroughly and
was allowed to incubate overnight in a 10-15°C water bath.

2.6.4 – Bacterial Transformation:

Chemically competent DH5α were purchased from Invitrogen (Cat. #18265-017)
and were used for both whole plasmid as well as complete ligated plasmid
transformations. In order to transform a plasmid into these bacteria, approximately 100
ng of whole plasmid (or typically 2-5 µL of a completed ligation reaction performed as in
section 2.7.3) was mixed with 30 µL of DH5α bacteria and incubated on ice for 30
minutes. The bacteria/plasmid mixture was placed into a 42°C water bath for 30 seconds
in order to “heat shock” the bacteria, in turn allowing the plasmid DNA to efficiently
enter the bacteria. After heat shock, the mixture was placed back on ice for an additional
2 minutes. Then, 250 µL of SOC media (Corning Cellgro Cat# 46-003-CR) was added to
the mixture and incubated in a 37°C water bath for 1 hour. After this incubation the
mixture was plated on LB agar plates containing the relevant antibiotic depending upon
the resistance marker of the plasmid (either Ampicillin with a concentration of 100µg/mL
or Kanamycin at a concentration of 50µg/mL). For whole plasmid transformations, 50 µL
of the final mixture would be added to the LB agar plate; however, for transformations of
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DNA ligation, the entire volume of the transformation would be added to two plates (we
would add 125 µL per plate on two separate plates), as the transformation efficiency from
DNA ligations would be far less than whole plasmid transformations. The plates were
placed in a 37°C incubator overnight.

2.6.5 – Plasmid Purification:

Following a successful plasmid transformation, individual colonies from the LB
agar plates would be selected and grown in LB broth media supplemented with the
relevant antibiotic at the concentrations listed in section 2.7.6, and were incubated using a
37°C shaker at 300 RPM. The colonies were expanded to either 5 mL overnight cultures
for mini-prep (small scale) purification; however, for midi-prep (large scale) purification,
colonies expanded to a 5 mL culture for approximately 8 hours were then added to 75 mL
of LB broth media and incubated at 37°C overnight. DNA plasmids were extracted and
purified using either mini-prep (purchased from Qiagen, Cat. #27106) or midi prep kits
(purchased from Sigma, Cat. #NA0200-1KT). Both mini- and midi-prep plasmid
purification techniques were performed following the manufacturer’s protocols. Once the
plasmid purifications were complete, we obtained the plasmid concentrations using a
Nano-Drop instrument (part of the DNA sequencing core, purchased from Thermo
Scientific).
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2.7 – Biological Assays:

Attempting to address the hypotheses of this project required the use of several
state of the art biological techniques and assays. Some of the important goals involved
identifying novel protein-protein interactions, studying protein stability as well as posttranslational modifications, and induction of cellular senescence. The biological assays
used to answer these questions included the following: immunoprecipitations, western
blot analysis, luciferase assays, and senescence assays. The detailed explanations of how
these assays were performed, as well as data analysis resulting from these assays, are
listed below.

2.7.1 – Immunoprecipitations:

One of the most common and applicable techniques used to study protein-protein
interactions is the coimmunoprecipitation assay. This technique involves agarose beads
that typically have an antibody conjugated to them, which allows for the precipitation of
a particular protein. By pulling down proteins of interest using such antibody-conjugated
beads, one can look for the presence of other proteins that interact with it. From a
theoretical standpoint, coimmunoprecipitations are considered relatively straightforward;
however, such a technique can be quite difficult, especially at the endogenous,
physiological level. Detailed below are procedures involved for coimmunoprecipitations
that were performed, both at the over-expressed and endogenous level.
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2.7.1.1 – Immunoprecipitation of Over-Expressed Proteins

Coimmunoprecipitations of over-expressed proteins were generally performed 24
hours post-transfection (as described in Section 2.6) of cells that were plated in 60mm
dishes. Cells were lysed in 300µL of Modified RIPA buffer (in some cases, more or less
might be used depending upon cell confluency), which consists of 50mM Tris-HCl
pH7.4, 200mM NaCl, and 1% NP-40. Modified RIPA buffer was supplemented with a
protease inhibitor cocktail (Sigma) and 1 mM sodium orthovanadate. Cells were
harvested using a cell scraper, transferred to eppendorf tubes, and placed on a rotator for
4 hours at 4°C. After the incubation, each sample was syringed 6-8 times using a 25
gauge syringe needle, followed by a max speed centrifuge for 3 minutes at 4°C. The
supernatant was removed from the insoluble pellet, placed in a new eppendorf tube, and
quantified using a Bio-Rad protein quantification assay (Cat. #500-0006). Typically, 1
mg of protein was used and additional Modified RIPA buffer was added to each sample
to make a total volume of 1 mL (giving us consistent samples of 1 mg/mL). Then,
agarose beads with the relevant epitope tag were added according to the respective
manufacturer protocol: either 5 µL of GFP (GFP-Trap® Beads from Allele
Biotechnology, Cat. #ABP-NAB-GFPA100), HA (Sigma, Cat. #A2095-5ML), or FLAG
(Anti-Flag M2 Affinity Gel from Sigma, Cat. #A2220-5ML) conjugated agarose beads
were used per sample. In all coimmunoprecipitation experiments using such beads,
lysates were rotated overnight at 4°C. The following day, the immunoprecipitations were
centrifuged for 2 minutes at 3000 RPM using a refrigerated centrifuged to pellet down the
beads. The supernatant was removed and the beads were washed with 500 µL of
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Modified RIPA buffer. This washing procedure was repeated a total of three times. At the
last wash step, the beads were re-suspended in 12 µL of RIPA buffer and 4µL of 4X
NuPAGE LDS sample running buffer. The IPs, along with 50 µg of whole cell lysate per
sample, were run on a SDS-PAGE gel and analyzed by western blot as described in
Section 2.8.2.

2.7.1.2 – Immunoprecipitation of Endogenous Proteins:

As endogenous proteins do not have epitope tags that can be immunoprecipitated
using antibody-conjugated beads, the protocol for coimmunoprecipitation of endogenous
proteins varies to the one used for over-expressed proteins. Again, cells were lysed in
Modified RIPA buffer; however, in this particular case 3 mg of total purified protein was
placed in a final volume of 1 mL (protein lysate plus Modified RIPA buffer). First, a
primary antibody against the protein of interest was added and rotated at 4°C overnight.
The following day, 15 µL of an agarose conjugated secondary antibody (Rockland Cat.
#00-8811-25) was added and rotated for 4 hours at 4°C as to bind to the primary antibody
that is now attach to the protein of interest. The agarose beads were again washed three
times with Modified RIPA buffer as previously described (Section 2.8.1.1). Following
the wash steps, the beads were resuspended in 12 µL of RIPA buffer and 4 µL of 4X
NuPAGE LDS sample running buffer. The immunoprecipitations, along with their
relevant controls (which included lysate with no primary antibody and buffer with
primary antibody) and whole cell lysate, were analyzed by western blot analysis.
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2.7.2 – Western Blotting:

Whole cell lysates, as well as any immunoprecipitation samples, were combined
with a 4X LDS sample buffer purchased from Invitrogen (Cat. # NP0007) made in the
following manner: 450 µL of LDS sample buffer plus 50 µL of β-Mercaptoethanol
purchased from Sigma (Cat. # M6250-100ML). The 4X LDS sample buffer was added to
sample to give a final concentration of 1X. Whole cell lysates and IPs (which were
vortexed thoroughly) were heated at 95°C for 10 minutes in order for efficient
denaturation of protein. Once the protein samples were prepared, they were loaded on a
pre-cast 10% Bis-Tris Polyacrylamide Gel obtained from Invitrogen (Cat. #NP0302BOX)
and was filled with 1X MOPS SDS Running Buffer (Cat. #NP0001). All protein gels
were run at 120 Volts until the gels had run to completion (indicated by the loading dye
reaching the bottom of the gel). The gel was then removed from the casting tray and
prepared for the transfer phase.
Protein gels were transferred onto a 0.2 µm pore size nitrocellulose membrane
using a complete immersion (wet) transfer in 1X Transfer Buffer (Cat. #NP0006-1),
which was made in the following manner: 50 mL of 20X Transfer Buffer, 200 mL of
methanol, and 750 mL DI water. The prepared transfer buffer was always pre-chilled in a
-20°C freezer before use. All protein gels were transferred at 35 volts for approximately
three hours.
Following the transfer phase, nitrocellulose membranes would be washed in 1X
TBST solution for 5 minutes and then blocked in a 5% milk in 1X TBST solution for 1
hour. After blocking, the membranes (blots) would be incubated in primary and
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secondary antibodies as previously described in Section 2.3. Between primary and
secondary antibodies, as well as after secondary antibody removal before West PICO
ECL detection, blots were washed in 1X TBST 3 times for 5 minutes and one additional
time for 10 minutes. Blots were immersed in West PICO ECL solution for 2 minutes and
exposed to chemi-luminescent detection film purchased from MidSci™ (Valley Park,
MO) (Cat. #EBA45).

2.7.3 – Generation of Stable Rb Knockdown Cell Lines:

In order to effectively study the significance of Rb in NORE1A mediated
senescence, we generated a matched pair of A549 cell lines that were either wild-type or
stably knocked down for Rb expression. To generate Rb knockdown cells, 293FT cells
were transfected with the pLKO-Rb knockdown constructs (described in Section 2.1) and
a mixture of the viral packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen) at a
ratio of 1:3, using JetPRIME™ transfection reagent. Approximately 48 to 72 hours
following transfection, supernatant containing viral particles was harvested and clarified
by centrifugation at 2000 RPM for 5 minutes. 2 mL of the clarified viral supernatant
containing 4 g/mL polybrene was added to A549 cells and the cells incubated for 1216hr at 37C. This viral transduction step was repeated once more. After the second
transduction step, cells stably transduced with the knockdown constructs were selected in
1g/ml of puromycin purchased from Sigma (Cat. #P8833-10MG) and used as an early
passage pooled population. All aspects involving the generation of Rb knockdown cell
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lines were carried out by Dr. Howard Donninger, and the validation of the matched
paired cell system was performed by western blot analysis.

2.7.4 – Senescence Assays:

The main focus of this project was to elucidate the mechanisms by which
NORE1A can promote the induction of senescence. While there are several established
markers of senescence, the gold standard used to study cellular senescence is by an
increase in β-galactosidase activity that can be detected at a sub-optimal pH (246). For
the purposes of this project, we purchased a senescence detection kit from BioVision Inc.
(Milpitas, CA) (Cat. #K320-250) that can be used to detect β-galactosidase activity from
mammalian cells grown in culture. We performed senescence assays in MEFs (wild-type
MEFs have the senescence machinery intact) and A549s (that can be induced for
senescence by NORE1A transfection) (20). For MEFs and A549s, approximately 50,000
cells were seeded per well in 12-well plates. The day after plating, cells were transfected
with the relevant expression constructs (as described in Section 2.5), and fresh media
added every 24 hours for 72 hours post-transfection. Cells were then stained for βgalactosidase as recommended by the manufacturer’s protocol. The scoring of the assay
was performed by counting five random fields of view per well, doing a ratio of the
number of β-galactosidase positive stained cells to the total number of cells in the field of
view. This allows for a percentage of cells undergoing senescence. For senescence assays
involving PP1A siRNAs, the siRNAs were transfected first and the transient transfection
of NORE1A would be performed the following day. These cells were incubated for an
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additional 72 hours before β-galactosidase staining. For any senescence assay that was
performed in this dissertation, the relative expression of GFP-tagged NORE1A was taken
48 hours post-transfection to ensure consistent transfection efficiency throughout the
experiment.

2.7.5 – Luciferase Assays:

Luciferase assays were performed using reagents using the LightSwitch™
luciferase assay kit with a corresponding luciferase reporter construct containing the IL-6
promoter generated by Active Motif (Carlsbad, CA). A549 +/- Rb cells (described in
Section 2.8.2) were plated at a concentration of 5,000 cells per well in a 96-well plate.
These cells were transfected with the IL-6 promoter luciferase construct in the presence
or absence of GFP-NORE1A, and were incubated for 48 hours. Before performing the
luciferase assay, pictures were taken to show consistent expression of GFP-vec/NORE1A
throughout the experiment. Cells were lysed according to the manufacturer’s protocol,
and the samples were read using a Lumat LB 9507 from Berthold Technologies (Oak
Ridge, TN). The data was analyzed using the Relative Luciferase Units (RLU).

2.8 – Image Acquisition, Processing, and Statistical Analysis:

A Pharos FX plus Molecular Imager from BioRad (Hercules, CA) was used to
digitize images prior to quantification using Quantity One software (BioRad). Figures
were compiled using Photoshop software (Adobe). All data are reported as mean ±
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standard deviation. Difference between treatment groups were tested using a two-sided
Student’s t-test as appropriate. Data was considered statistically significant where p<0.05.
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CHAPTER 3

RAS REGULATES RB VIA NORE1A

3.1 – Introduction:

Ras mutations are the most frequent oncogenic events in human cancer and can be
found in approximately 30% of all human cancers (247). In experimental systems,
activated forms of Ras can be powerfully transforming, and transgenic animal models
have validated the role of Ras activation in tumorigenesis (8,248). However, despite the
extensive evidence linking Ras to transformation and tumor development, activated Ras
can also promote a state of irreversible cell cycle arrest called oncogene induced
senescence (159,249). This tendency for deregulated Ras activity to provoke senescence
can be observed in Ras driven tumors (246). It appears that senescence provides a potent
barrier to suppress the development of Ras driven cancer, as malignant tumors lose the
senescence phenotype (246). The exact mechanisms by which Ras can promote
senescence are not completely understood, but it appears the main Ras senescence
pathways involve the p53 and Rb tumor suppressors (250). Initial evidence in mouse
embryonic fibroblasts (MEFs) suggests that loss of functional p53 or Rb pathways alone
is sufficient for Ras to bypass senescence (159). More recent studies show that in vivo,
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suppression of p53 function (251) or Rb (252) enhances Ras mediated transformation in
murine systems. However, human systems may require inactivation of both p53 and Rb
for full senescence evasion (253). Thus, inactivation of p53 and Rb senescence pathways
may be essential for Ras-induced transformation.
In addition to the classic trio of growth promoting Ras effector proteins, Raf, PI-3
kinase and RalGDS, Ras also interacts with growth suppressing effector proteins,
including NORE1A (RASSF5) (6,254). NORE1A is a member of the RASSF family of
tumor suppressors that is frequently down-regulated during tumor development, and its
inactivation has been linked to a rare familial cancer syndrome (13,15,18). NORE1A
binds directly to Ras (19) and is thought to act as a scaffolding protein as it lacks any
apparent enzymatic activity. NORE1A connects Ras to the pro-apoptotic Hippo pathway
(19) and has apoptotic properties (12). NORE1A-/- MEFs are predisposed to Ras-induced
transformation, unlike wild-type MEFs which require inactivation of p53 or Rb to allow
transformation by Ras (255). Furthermore, up-regulation of Ras activity in primary
tumors is often correlated with inactivation of NORE1A (15,256). Thus, NORE1A acts
as a potent barrier against aberrant Ras signaling, and loss of NORE1A allows Ras to
circumvent its own growth inhibitory properties, shifting the balance of Ras activity
towards transformation (20).
We have recently shown that NORE1A is a powerful Ras senescence effector that
acts via p53 (20). NORE1A forms an endogenous, Ras regulated complex with the kinase
HIPK2, which can regulate both the phosphorylation and the acetylation of p53. In turn,
NORE1A scaffolds HIPK2 to p53 and stimulates pro-senescent p53 acetylation.
Although we found that NORE1A induced senescence is heavily dependent upon p53, we
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noticed that NORE1A retained partial senescence inducing activity even when nearly all
detectable p53 had been eliminated from the system (20), suggesting that additional
mechanisms are required for the effects of NORE1A on senescence to fully manifest.
In addition to p53, Ras can promote senescence induction by activating the Rb
pathway. The Retinoblastoma (Rb) gene was the first identified tumor suppressor gene in
rare cases of pediatric tumors of the retina called retinoblastoma (199,222,257).
Furthermore, alterations in the Rb gene or inactivation of the Rb protein have been
identified in a variety of human cancers (258,259), and it is now widely accepted that the
inactivation of the Rb protein may be one of the most frequent events in cancer (260). In
addition to its important function in regulating the cell cycle, recent evidence points to Rb
having critical functions in other biological processes, including chromosomal stability,
regulation of apoptosis, and oncogene induced senescence (159,261,262). Inactivation of
Rb in vitro or in vivo suppresses Ras-induced senescence (159,252), implicating Rb as an
important effector of Ras mediated senescence. Thus, while it appears that Ras activates
senescence, in part, via Rb, exactly how Ras modulates Rb activity remains unclear.
Rb regulation is complex and involves both inhibitory phosphorylation and
activating dephosphorylation events. While the mechanisms of Rb phosphorylation by
cyclin-dependent kinases are well characterized (231), the processes that activate Rb by
dephosphorylation remain unclear. Recent reports have shown that the phosphatases PP1
and PP2A play important roles in the mammalian cell cycle (263-265). Moreover, it has
been shown that PP1 phosphatases can act on Rb to promote the formation of the active,
hypophosphorylated form of the protein (232,236). Intriguingly, PP1A enzymatic activity
can be regulated by Ras (237). Thus, PP1A might serve as the link between Ras and Rb,
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and Ras may, in part, promote senescence by activating PP1A, thereby promoting the
dephosphorylation and activation of Rb (22). Exactly how Ras stimulates the activity of
PP1A towards Rb remains obscure.
PP1A, a key regulator of Rb activity, was first detected in complex with
NORE1A in a yeast two-hybrid system (23), and since we have recently established that
NORE1A mediated Ras-induced senescence is only partly driven by p53, we sought to
determine if NORE1A could also be modulating senescence by regulating Rb function.
We now show that NORE1A regulates the dephosphorylation of Rb by forming an
endogenous, Ras regulated, complex with PP1A, scaffolding it to Rb and enhancing the
Rb/PP1A complex. Moreover, suppression of Rb suppresses NORE1A induced
senescence. Thus, we now identify a powerful new mechanism by which Ras can induce
senescence via regulating the phosphorylation status of Rb. Therefore, NORE1A acts as a
critical node linking both p53 and Rb to Ras. This may explain why Ras driven tumors
often exhibit reduced NORE1A expression (256).

3.2 – Results:

NORE1A forms an endogenous, Ras regulated complex with PP1A –NORE1A is
primarily localized to the nucleus (20), and has been observed to shuttle between the
cytoplasmic/nuclear cell fractions (266). However, the localization pattern of PP1A is
more complex. PP1A exhibits diffuse expression in the cytoplasm and the nucleoplasm,
but also accumulates in unidentified nuclear bodies (267). Since NORE1A also occurs in
nuclear speckles, we determined whether NORE1A and PP1A co-localized in
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mammalian cells using transient transfections of the fluorescently tagged proteins. We
found that a pool of GFP-PP1A specifically co-localized with KATE-NORE1A in the
nucleus (Figure 6). The KATE protein is a far red fluorescent protein that gives bright
far-red fluorescence to easily detect proteins engineered to contain a fused KATE tag
(268,269). An empty KATE vector was used as a negative control.
To determine if NORE1A and PP1A can be found in a complex, we performed
coimmunoprecipitations in HEK-293T cells co-transfected with NORE1A and PP1A in
the presence or absence of activated Ras. We found that NORE1A does complex with
PP1A. Furthermore, the results show that the interaction of NORE1A and PP1A is
significantly enhanced in the presence of activated Ras (Figure 7A). Further analysis
confirmed that endogenous NORE1A could be coimmunoprecipitated with endogenous
PP1A from the HepG2 human liver hepatocellular carcinoma cell line (Figure 7B),
confirming that the NORE1A/PP1A interaction is physiologically relevant.

Ras/NORE1A Stabilize PP1A – While studying the effects of Ras on the
NORE1A/PP1A interaction, we observed an increase in the levels of PP1A in whole cell
lysates in the presence of Ras and NORE1A. We hypothesized that Ras/NORE1A could
be promoting PP1A stability. To address this, we analyzed the effects of NORE1A and
Ras on PP1A protein stability by using cycloheximide treatment after transient
transfections in HEK-293 cells. While the results show that Ras or NORE1A individually
did not seem to promote the stability of PP1A, the presence of both Ras and NORE1A
together lead to a statistically significant (P<0.05) increase in PP1A expression, even 24
hours after cycloheximide treatment (Figures 8, 9). Thus, it seems that Ras and NORE1A
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GFP-PP1A
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GFP-PP1A

KATE-NORE1A

Merge

Figure 6. Exogenously expressed NORE1A and PP1A co-localize in the nucleus.
COS-7 cells were transfected for 48 hours with GFP-PP1A in the presence or absence of
KATE-NORE1A. While PP1A can be found throughout the cell, there is an important
pool of PP1A strongly co-localizing in the nucleus with NORE1A. Representative images
were taken using an IX50 inverted system microscope (Olympus) and a SPOT camera
(Diagnostic Instruments Inc.).
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Figure 7. NORE1A forms an endogenous, Ras regulated complex with PP1A. A.
Activated Ras enhances the interaction between NORE1A and PP1A. HEK-293T cells
were co-transfected with expression constructs for PP1A, NORE1A, and activated H- or
K-Ras for 24 hours. Cells were then lysed and equal amounts of protein extracts were
immunoprecipitated with anti-GFP. The immunoprecipitates were analyzed by western
blotting with anti-HA and anti-GFP antibodies. B. NORE1A and PP1A are found in an
endogenous complex. HepG2 cells were immunoprecipitated (IP) for NORE1A and
immunoblotted (IB) for PP1A. IgG incubated with HepG2 lysates and Ig/NORE1A
antibody incubated with lysis buffer served as negative controls.
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Figure 8. Ras/NORE1A stabilizes PP1A. HEK-293 cells were transfected with PP1A,
NORE1A, and activated H-Ras expression constructs for 24 hours. The cells were treated
with cycloheximide (20 µg/mL) and lysed at the indicated times after addition of
cycloheximide. Levels of PP1A protein were measured by western blot analysis. Shown
is a representative blot of three independent experiments. The density of the bands was
quantitated using ImageJ software and relative PP1A expression was calculated after
normalizing to β-Actin expression. In cells transfected with both NORE1A and Ras, there
was a statistically significant increase in the levels of PP1A (P<0.05).
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Figure 9. Quantification of the relative PP1A expression in the presence and absence
of NORE1A and activated H-Ras following cycloheximide treatment. Quantification
of three independent experiments was performed, which is shown as a representative
image in Figure 8. Briefly, the blots were quantified densitometrically to calculate the
relative amount PP1A in the presence or absence of NORE1A and H-Ras-12V following
cycloheximide treatment. *, P<0.05 compared to cells transfected with GFP-PP1A alone.
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cooperate to promote PP1A stability. Since NORE1A regulates the stability of other
target proteins via the proteasome (194), we sought to determine whether Ras/NORE1A
may be similarly regulating PP1A stability. We co-transfected HEK-293T cells with
PP1A and an HA-ubiquitin-1 expression construct in the presence and absence of
NORE1A and activated Ras, treated the cells with the proteasome inhibitor MG132,
immunoprecipitated the PP1A and analyzed the immunoprecipitates for ubiquitinated
PP1A by western blotting with an anti-HA antibody. Although the levels of ubiquitinated
PP1A appear reduced in the Ras/NORE1A sample (Figure 10), quantification of multiple
experiments showed that the apparent decrease was not statistically significant. This
suggests that the stabilization effect may be independent of the proteasome system.

NORE1A forms an exogenous, Ras regulated complex with Rb – PP1A is a
phosphatase that binds to Rb and modulates its activity by dephosphorylation (270).
Since we have now established an endogenous interaction between NORE1A and PP1A,
it is plausible that NORE1A could be found in a complex with Rb. We first wanted to
determine if the proteins co-localize in the cells. To address this, we co-transfected COS7 cells with GFP-tagged Rb in the presence of either KATE-vector (used as a negative
control) or KATE-NORE1A for 48 hours. We did find strong co-localization of the two
proteins within the nucleus (Figure 11A). To confirm that the proteins interact, we cotransfected HEK-293T cells with NORE1A and Rb in the presence and absence of
activated Ras and found that NORE1A coimmunoprecipitated with over-expressed Rb,
and that this interaction was enhanced in the presence of Ras (Figure 11B).
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Figure 10. Ras/NORE1A do not significantly alter proteosomal degradation of
PP1A. HEK-293 cells were transfected with expression constructs for PP1A, NORE1A,
activated H-Ras and Ubiquitin-1 for 24 hours. The cells were then treated with the
proteosome inhibitor MG132 for 4 hours, lysed and equal amounts of protein
immunoprecipitated with anti-GFP. The immunoprecipitates were analyzed by western
blotting with anti-HA, anti-GFP and anti-FLAG antibodies. The density of the bands was
quantitated using ImageJ software and the relative amount of ubiquitinated PP1A was
calculated after normalizing to the total amount of PP1A immunoprecipitated. Although
there appeared to be less ubiquitinated PP1A in the presence of both NORE1A and
activated Ras compared to the vector control, this was not statistically significantly
different.
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Figure 11. NORE1A complexes with Rb. A. Exogenously expressed NORE1A and Rb
co-localize in the nucleus. COS-7 cells were transfected for 48 hours with GFP-Rb in the
presence or absence of KATE-NORE1A. B. NORE1A forms a Ras regulated complex
with Rb. HEK-293T cells were co-transfected with expression constructs for Rb,
NORE1A, and activated H-Ras for 24 hours. The cells were then lysed and immunoprecipitated with anti-GFP. The immunoprecipitates were analyzed by western blotting
with anti-HA and anti-GFP antibodies. *, P<0.05 compared to cells transfected with
NORE1A alone (quantification of three independent experiments).
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NORE1A Cooperates with Ras to Scaffold PP1A to Rb – NORE1A is a tumor
suppressor that is thought to act primarily as a scaffolding molecule, as it has no apparent
enzymatic activity (15,191,194). We have recently identified a Ras mediated mechanism
by which NORE1A scaffolds HIPK2 to p53 in order to promote the pro-senescent
functions of p53 (20). Thus, a similar mechanism may be occurring here where NORE1A
acts to scaffold PP1A onto Rb in a Ras dependent manner. To test this, we co-transfected
HEK-293T cells with Rb, PP1A, and NORE1A expression constructs in the presence or
absence of activated Ras, immunoprecipitated the NORE1A and immunoblotted for the
presence of both Rb and PP1A. We found that both PP1A and Rb could be found in a
complex with NORE1A simultaneously, and the levels of both PP1A and Rb in the
complex with NORE1A increased in the presence of activated Ras (Figure 12). To
confirm that NORE1A was scaffolding PP1A to Rb, we transfected HEK-293T cells with
Rb and PP1A, in the presence and absence of NORE1A and activated Ras, and examined
the effects of Ras and NORE1A on the complex formation between PP1A and Rb. The
results show that indeed, the Rb/PP1A complex is enhanced by NORE1A, and that this
effect is further increased in the presence of activated Ras. A representative blot is shown
in Figure 13 and quantification of two independent experiments is shown in Figure 14.
Exactly how Ras facilitates the interaction between NORE1A and PP1A and Rb is not
entirely clear. However, binding of Ras to NORE1A induces a conformational change
(271), and this may promote the interaction between NORE1A and its binding partners.

NORE1A promotes the dephosphorylation of Rb at Serine 795 – The activity of
Rb is primarily regulated by its phosphorylation status at several Ser/Thr residues, and Rb
can be activated when Ser/Thr phosphatases promote its dephosphorylation (231). Since
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Figure 12. PP1A and Rb are found in a Ras regulated complex with NORE1A. HEK293T cells were co-transfected with PP1A, Rb, NORE1A and activated H-Ras expression
constructs for 24 hours. The cells were lysed and equal amounts of protein
immunoprecipitated with anti-FLAG. The immunoprecipitates were analyzed by western
blotting with anti-GFP, anti-HA, and anti-FLAG antibodies.
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Figure 13. Ras regulates the interaction between PP1A and Rb via NORE1A. HEK293T cells were co-transfected with expression constructs for PP1A, Rb, NORE1A, and
activated H-Ras for 24 hours. Cells were lysed and immunoprecipitated for GFP-PP1A,
and the immunoprecipitates analyzed by western blot analysis with anti-HA, GFP, and
FLAG antibodies.
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Figure 14. Quantification of the relative fold increase in Rb/PP1A interaction.
Quantification of three independent experiments was performed, which is shown as a
representative image in Figure 12. Briefly, the blots were quantified densitometrically to
calculate the relative amount of Rb found in complex with PP1A. *, P<0.05 compared to
cells transfected with empty vector, **, P<0.05 compared to cells transfected with either
NORE1A or activated Ras alone.
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NORE1A forms an endogenous complex with PP1A, a key mediator of Rbdephosphorylation, and scaffolds it to Rb, we sought to determine if NORE1A could
promote the dephosphorylation of Rb. By using a phospho-specific antibody to Ser-795, a
residue known to be regulated in part by PP1A (272), we examined the effects of
NORE1A on Rb phosphorylation. In transient transfections of A549 cells (a mutant KRas NORE1A negative, p53 positive lung tumor cell line (17)), we observed that
NORE1A decreased the phosphorylation of endogenous Rb at Serine 795 (Figure 15A).
In addition, we examined the phosphorylation status of endogenous Rb in NCI-H1299
lung cancer cells (mutant Ras positive, NORE1A negative, p53 negative (273)) stably
expressing NORE1A at more physiological levels (194), and found similar results
(Figure 15B). To confirm the link between NORE1A and Rb phosphorylation, we
transiently knocked down NORE1A in HEK-293 cells using two previously validated
shRNA constructs to NORE1A (20), and found that indeed loss of NORE1A enhanced
the phosphorylation of Rb at Serine 795 (Figure 16). Thus, it seems that NORE1A may
be a crucial mediator of Rb function by regulating its phosphorylation status.

Rb is a downstream effector of NORE1A induced senescence – We have recently
shown that NORE1A is a critical Ras senescence effector that acts by forming a Ras
regulated complex with p53 (20). However, although suppression of p53 strongly
impaired the NORE1A senescence phenotype, it did not completely abolish it. This
suggests that NORE1A may be able to promote senescence via additional mechanisms.
Since the Rb pathway is one of the most powerful effector pathways of Ras-induced
senescence, and we have now shown that NORE1A can regulate the dephosphorylation
of Rb, we sought to determine if NORE1A can promote senescence through Rb in
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Figure 15. NORE1A promotes Rb dephosphorylation. A. A549 cells, which do not
express NORE1A, were transiently transfected with GFP-NORE1A for 24 hours. Cells
were lysed and immunoblotted for Rb phosphorylated at Serine-795 using a S795specific antibody. B. NCI-H1299 cells stably expressing NORE1A or an empty vector
were lysed an immunoblotted for phospho-RB at Serine 795. Shown are representative
blots of two independent experiments.
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Figure 16. Loss of NORE1A enhances Rb phosphorylation. HEK-293 cells were
transiently knocked down for NORE1A expression using two different shRNA constructs
to NORE1A. The cells were lysed 48 hours following transfection and were immunoblotted for phospho-Rb at Serine 795.
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addition to p53 in order to fully promote its senescent phenotype. To address this
question, we transfected NORE1A into wild type and Rb-/- MEFs and measured
senescence by β-galactosidase activity. As we have previously shown, NORE1A induces
senescence in wild-type MEFs, but in the absence of Rb, NORE1A was unable to induce
senescence (Figure 17A and B). This suggests that NORE1A requires Rb in order to
induce senescence in primary murine fibroblasts.
A459 cells are a human lung adenocarcinoma cell line that expresses wild type
p53 and Rb, but do not express NORE1A (17). To confirm the role of Rb in NORE1A
mediated senescence in human cells, we generated A549 cells that were knocked down
for Rb using two different shRNAs to Rb (Figure 18). We then transiently transfected
NORE1A into these cells, and assayed senescence by β-galactosidase activity. As
expected, NORE1A was able to promote senescence in the cells stably transfected with
the scramble control, but its ability to drive senescence was severely, although not
completely, suppressed in the cells knocked down for Rb expression (Figure 19A and
B). To substantiate that the elevated levels of β-galactosidase staining observed in these
cells was senescence-related, we measured effects on IL-6 expression, an additional wellestablished marker of senescence (246). NORE1A induced a significant (P<0.05)
increase in IL-6 promoter activity in the A549 cells, which was abrogated in the absence
of Rb (Figure 20). Thus, in addition to p53, NORE1A also appears to act via Rb to fully
promote senescence.

PP1A-mediated dephosphorylation of Rb is required for NORE1A Induced
senescence – We have established that NORE1A interacts with PP1A, enhances the
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Figure 17. Loss of Rb significantly impairs NORE1A mediated senescence in MEFs.
Wild-type and Rb-/- MEFs were transfected with 1 µg pcDNA-HA-Vector or NORE1A.
Cells were incubated for 72 hours before assaying for β-galactosidase activity. *P≤0.05
compared with wild-type transfected MEFs.
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Figure 18. Generation of human lung cancer A549 +/- Rb matched pair cell system.
To study the effects of NORE1A on Rb and senescence, we generated a matched pair cell
system that would be wild-type or knocked down for Rb expression. The system was
generated using two different lentiviral expression constructs containing shRNAs to Rb.
Cells were validated by western blot analysis using an antibody to Rb.
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Figure 19. Rb is a downstream effector of NORE1A induced senescence in human
cells. A. Stable scrambled or sh-Rb transduced A549 cells were transfected with 1 µg
GFP-NORE1A. After 72 hours, the cells were assayed for β-galactosidase activity.
*P<0.05 compared with scrambled control transfected cells. B. Representative images of
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98

*

4000
3000
2000
1000

E1
A
R

sh
R

b#
2

/N
O
sh
R

b#
1

/N
O

/N
O

R

E1
A
R

to
Sc
rm

/v
ec
Sc
rm

E1
A

0
r

Luciferase Activity (RLU)

A

B.
Scrm/vector

Scrm/NORE1A

shRb#1/NORE1A

shRb#2/NORE1A

Figure 20. Rb is an effector of NORE1A induced IL-6 promoter activity. A. Control
and A549 cells stably knocked down for Rb described previously were co-transfected
with GFP-NORE1A and an IL-6 promoter luciferase reporter construct. Luciferase
activity was measured 48 hours after transfection using a LightSwitch Luciferase Assay
system. *, P<0.05. B. Representative images of NORE1A expression.
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complex formation with Rb, promotes the dephosphorylation of Rb and requires Rb for
senescence. To fully substantiate that the NORE1A mediated dephosphorylation of Rb by
PP1A is required for NORE1A induced senescence, we examined the ability of NORE1A
to promote the dephosphorylation of Rb and promote senescence in the absence of PP1A.
In the absence of PP1A, both NORE1A mediated dephosphorylation (Figure 21) and
senescence (Figure 22) were severely impaired, confirming that dephosphorylation of Rb
via PP1A is required for NORE1A mediated senescence.

3.3 – Discussion:

Oncogenic Ras mutations are critical drivers of transformation via promotion of
mitogenic signaling pathways (6). Paradoxically, Ras also regulates growth inhibitory
pathways such as apoptosis and senescence (148,159,274). Ras-induced senescence is a
major defense mechanism suppressing Ras driven transformation, and loss of functional
senescence pathways is necessary for Ras to manifest its full transforming potential
(246,275). While recent studies have confirmed the significance of Ras-induced
senescence in vivo, the mechanisms by which Ras can promote a senescent phenotype
both in vitro and in vivo remain poorly defined (246,276,277).
Two pathways that have been identified as key players in oncogene induced
senescence involve the p53 and Rb tumor suppressors. Early studies in primary rodent
cells suggested that loss of either the p53 or the Rb pathways was sufficient for Ras to
bypass senescence and promote transformation (159). In contrast, the loss of one of these
pathways typically only delays the onset of senescence in human cells. Recent studies
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Figure 21. Loss of PP1A impairs NORE1A induced dephosphorylation of Rb. A.
A549 cells were transiently knocked down for PP1A expression using a validated pool of
PP1A siRNA. The cells were transfected with GFP-NORE1A and 24 hours later, lysed
and immunoblotted for phosphor-Rb at Serine 795, Rb, PP1A, and NORE1A. B.
Quantification of two independent experiments was performed. Blots were quantified
densitometrically to calculate the relative amount of Rb phosphorylation at Ser-795. *,
P<0.05 compared to vec/scrm transfected cells. **, P<0.05 compared to vec/scrm and
NORE1A/scrm transfected cells.
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have shown that the activation of both the p53 and the Rb pathways is essential for
induction of senescence in a variety of human cell lines (159,164,253,278,279), and
furthermore, cross-talk between the p53 and Rb pathways could allow for additional
protection against oncogenic Ras bypassing senescence and promote tumorigenesis (250).
Until now, the mechanisms by which Ras regulates the p53 and Rb pathways to drive
senescence has been unclear.
NORE1A (RASSF5) is a member of the RASSF family of tumor suppressors
(15). Like other members, it binds directly to Ras and serves as an effector to promote its
growth inhibitory properties (12,19). The best characterized member of the RASSF
family is RASSF1A, which shares considerable homology to NORE1A. RASSF1A binds
and activates MST kinases, which then feed into the Hippo pathway to regulate the
transcriptional co-activators YAP1, YAP2 and TAZ. However, although NORE1A also
binds MST kinases (19), it does not seem to activate them (280). Moreover, deletion
mutagenesis has shown that the interaction of NORE1A with MST kinases is not required
for its ability to inhibit cellular growth (17). This suggests that NORE1A may be
different to RASSF1A, and act via non-Hippo components.
By inducing physiological expression levels of NORE1A in cells, we found
NORE1A plays a key role in p53-mediated cell-cycle arrest (191). This led us to
determine that NORE1A is a potent senescence effector of Ras that precisely regulates
the post-translational modification code of p53 (20). NORE1A forms a Ras-regulated
complex with p53 and the kinase HIPK2.

This scaffolding event is an essential

component of Ras-induced senescence, and results in the enhanced acetylation of p53 at
K320 and K382 residues. Acetylation of p53 at these residues activates pro-senescent
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transcriptional programs (20,281). However, we noted that although suppression of p53
severely reduced NORE1A induced senescence, it did not completely abolish it (20).
Thus, the role of NORE1A in Ras-induced senescence is likely more complex and may
work through additional senescence pathways.
We hypothesized that NORE1A may also be able to promote senescence by
regulating the Rb pathway, the other powerful senescence pathway in oncogene induced
senescence. Indeed, we found that loss of Rb in both MEFs and human cells suppressed
the powerful senescence phenotype promoted by NORE1A. Interestingly, the suppression
of either Rb or p53 alone in A549 cells did not completely inhibit NORE1A induced
senescence, consistent with the notion that human cells require the loss of both the p53
and Rb pathways in order to fully bypass senescence.
One of the main regulators of Rb activity is the PP1A phosphatase (282,283).
PP1A has been implicated in Ras-induced senescence (22) and Ras has been shown to
control the catalytic activity of PP1A (237). As PP1A specificity is often controlled by
targeting proteins (25), we wondered if NORE1A might serve as a direct connection
between Ras, PP1A and Rb. We found that NORE1A forms an endogenous, Ras
regulated complex with the phosphatase PP1A. As PP1A has been detected in complex
with NORE1A in a yeast two-hybrid system, the interaction is likely to be direct (23).
Furthermore, we found that NORE1A appears to scaffold PP1A to Rb in a Ras dependent
manner, as NORE1A could be co-precipitated with Rb and Ras/NORE1A enhanced the
interaction between PP1A and Rb. The scaffolding of Rb to its phosphatase results in Rb
dephosphorylation, a pro-senescent event (24). The exact mechanism by which Ras
activates this NORE1A-PP1A-Rb axis is not entirely clear since Ras is found
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predominantly on the cell membrane and the NORE1A/PP1A/Rb complex is located
primarily in the nucleus. One possibility involves a Ras-induced conformational change
of NORE1A (271) that enables it to interact with PP1A and/or Rb, and then shuttle them
as a complex into the nucleus via various nuclear transport proteins (266). Another
possible mechanism may involve additional Ras signaling pathways that act upon nuclear
NORE1A to activate it, thereby inducing it to complex with PP1A and Rb. Interestingly,
a pool of Ras has also been found located in the nucleus (284,285), raising the possibility
that NORE1A/Ras stimulation of PP1A/Rb is entirely nuclear.
During these studies, we also noticed that NORE1A seems to modulate the
stability of PP1A. Recent studies have shown that the ubiquitin ligase mdm2, a negative
regulator of Rb that contributes to tumorigenesis in part by destabilizing Rb (286), can be
found in an endogenous complex with PP1A (287), though the effects of mdm2 on PP1A
stability have not been elucidated. Interestingly, NORE1A has been shown regulate the
degradation of specific mdm2 targets (288). Thus, NORE1A could be regulating PP1A
stability through its interaction with mdm2, potentially by antagonizing the
ubiquitination/degradation properties of mdm2.
PP1A is not an Rb-specific phosphatase and can regulate the functions of a
variety of proteins in the cell by modulating their phosphorylation status. The specificity
of PP1A is dictated by targeting proteins (25). Our data suggests that NORE1A may
serve as a Ras regulated PP1A-targeting protein, directing PP1A to a specific set of
substrates, such as Rb. This may provide a novel mechanism whereby NORE1A mediates
its tumor suppressor function through modulating specific protein phosphorylation.
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Further studies will be necessary to identify any additional NORE1A targeted PP1A
substrates.
Our data provide evidence that NORE1A provides a major link between Ras and
Rb. Activated Ras signaling promotes the association of PP1A to Rb via NORE1A,
resulting in the activation of Rb and senescence. In the absence of NORE1A, PP1A
cannot effectively scaffold to Rb and activate it, resulting in senescence bypass and
allowing the growth promoting effects of aberrant Ras signaling to predominate (Figure
23). Thus, NORE1A acts as a double-barreled Ras senescence effector that connects Ras
to the two major senescence effectors in human cells, p53 (20) and Rb. This may explain
why NORE1A is such a powerful senescence effector and why it is so frequently downregulated during tumorigenesis (15), particularly in tumors with up-regulated Ras activity
(256).

106

Ras

Ras

NORE1A

NORE1A
NORE1A

X

PP1A

PP1A

Rb

Rb

SENESCENCE

PROLIFERATION

Figure 23. Schematic representation of the newly identified Ras/NORE1A/Rb
pathway. Our data points to a novel Ras/NORE1A/Rb pathway whereby Ras promotes
NORE1A mediated scaffolding of PP1A to Rb to promote its dephosphorylation. This
results in Rb activation and subsequently activates the senescence machinery. Loss of
NORE1A inhibits the proper dephosphorylation of Rb, in turn suppressing senescence
induction, allowing Ras to bypass the senescence barrier allowing it to promote
proliferation.
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CHAPTER 4

NORE1A REGULATES ADDITIONAL RB POST-TRANSLATIONAL
MODIFICATIONS AND PROMOTES ITS STABILITY

4.1 – Introduction:

While Ras oncoproteins have potent transforming properties, they can also
activate important growth inhibitory pathways, including apoptosis and senescence
(148,159,274,289). Work performed by Donninger and colleagues has recently identified
NORE1A as a key component of Ras-driven senescence by regulating the pro-senescent
post-translational modifications of p53 (20). The link between Ras/NORE1A and p53
appears to be primarily the kinase HIPK2, which has been shown to regulate apoptosis by
directly phosphorylating p53 at Serine 46, in turn enhancing the affinity of p53 for proapoptotic gene promoters (290,291). In addition, HIPK2 can recruit acetyltransferases
CBP/p300 and PCAF, which can acetylate p53 and modulate its transcriptional activity
(291-293). Acetylation of p53 at Lysine 382, in combination with phosphorylation at
Serine 46 shifts p53 towards apoptosis; however, without the phosphorylation of Serine
46, the acetylation of Lysine 382 drives p53 away from apoptosis and pushes it towards
the induction of senescence (281,294). NORE1A forms an endogenous, Ras-regulated
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complex with HIPK2, in turn promoting senescence not only by acetylating p53 at Lysine
382, but also by suppressing the phosphorylation of p53 at Serine 46 (20). It was also
shown that NORE1A can promote the acetylation of p53 at Lysine 320 (20), which has
been reported to enhance p53 association with the p21CIP1 promoter, in turn enhancing its
expression which can ultimately lead to senescence (295). Thus, NORE1A can regulate
the post-translational signature of p53 in order to activate senescence.
Rb is the other critical tumor suppressor involved in Ras-induced senescence. In
murine cells, abrogation of either p53 or Rb seems to be sufficient to suppress
senescence; however, in human systems, both the p53 and Rb pathways must be
inactivated in order for Ras to bypass senescence and drive transformation (253). As is
the case with p53, Rb undergoes numerous post-translational modifications that regulate
its tumor suppressive functions (296). Although the phosphorylation of Rb has been
extensively studied,

the

significance

of

non-phosphorylation

post-translational

modifications of Rb, including the acetylation and SUMOylation, remains quite unclear.
It has been proposed that active Rb is both acetylated and hypophosphorylated.
Rb has recently been shown to be acetylated at the C-terminus by p300, which hinders
the phosphorylation of Rb by cyclin-dependent kinases (297), leading to the maintenance
of Rb in its active, hypophosphorylated form. As a result, such cells are maintained in a
growth arrested state. It is believed that some unknown cellular protein functions to
bridge p300 and Rb into a multi-protein complex to facilitate Rb acetylation. In addition
to p300, it has been recently shown that the p-300 Associated Factor (PCAF) can mediate
Rb acetylation, as Rb interacts directly with the acetyltransferase domain of PCAF in
vitro and can associate with PCAF in differentiated cells (298). PCAF acetylates Rb to
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induce Rb mediated terminal cell-cycle exit and expression of late myogenic genes (298).
Lastly, Tip60, a MYST-related HAT, catalyzes Rb acetylation in order to control Rb
expression levels (299). Collectively, evidence points to a new level of Rb regulation, and
stability, caused by differential acetylation of the Rb protein.
Protein acetylation is a reversible reaction. Interestingly, sirtuin 1 (SIRT1) not
only deacetylates histones (300) but other non-histone proteins, such as p53 (301-303). A
recent report by Wong and colleagues showed that Rb is a substrate for deacetylation by
human SIRT1 (304). Their work showed that acetylated Rb increases in response to
contact inhibition, and that over-expression of SIRT1 reduced the levels of Rb acetylation
in vivo. They hypothesize that the active form of Rb is both acetylated and hypophosphorylated, and that SIRT1-mediated deacetylation is required to deactivate Rb
(304). Again, evidence points to the role of Rb acetylation as an activating event the may
be required to promote its tumor suppressive functions. We have now shown that
NORE1A can regulate the pro-senescent function of Rb via dephosphorylation. But since
NORE1A has been shown to regulate multiple post-translational modifications of p53 in
order for senescence to fully manifest itself, we hypothesize that a similar mechanism
might be occurring with Rb, whereby NORE1A regulates both the phosphorylation and
the acetylation of Rb. The regulation of acetylation could involve the modulation of
acetyltransferases, such as PCAF and p300, as well as deacetylases such as SIRT1.
In addition to acetylation, Rb can be regulated by SUMOylation. Similar to
ubiquitination, SUMOylation involves the covalent attachment of a small peptide moiety
called SUMO (Small Ubiquitin-like Modifier) to specific lysine residues on a target
protein that can have profound effects on protein function, from influencing protein-
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protein interactions to sub-cellular localization and protein stability (296). Though the
significance of Rb SUMOylation remains somewhat undetermined, several studies have
shown that hypophosphorylated Rb can be SUMOylated by SUMO-1 and by SUMO-2/3
(305,306). The site of Rb SUMOylation was mapped to Lysine 720, and SUMOylation
enhanced the ability of Rb to repress E2F transcription (305). In addition, the conjugation
of SUMO can in some instances block the sites of attachment for ubiquitin, and can thus
protect proteins from degradation (307). Therefore, it is plausible that the SUMOylation
of Rb can promote its stability, raising the possibility that Rb can be both qualitatively
and quantitatively regulated. We hypothesize that the SUMOylation of Rb is critical for
its activation. Perhaps a reason why this fairly ubiquitous modification has only been
recently identified and studied lies in the reversibility of the process and the fact that,
apart from a very few exceptions, the amount of any SUMO-modified protein within a
cell only makes up a very small percentage of its total amount, thus making detection by
various molecular and biochemical methods more challenging (308). Because
preliminary evidence in our laboratory suggested that Ras/NORE1A can affect the
SUMOylation levels of proteins, such as HIPK2 (data not shown), we hypothesized that
NORE1A may also be regulating the SUMOylation of Rb to activate Rb function.
Protein inhibitors of activated STAT (PIAS) have been shown to function as E3
SUMO ligases, and data from various SUMO conjugates make them one of the largest
families of SUMO-specific ligases (309). The expression levels of one of the family
member, PIASy, was shown to be significantly elevated during senescence when
compared to pre-senescent cells, as do levels of hyper-SUMOylated proteins (310). In
addition, over-expression of PIASy induces premature senescence, and this effect
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requires its E3 SUMO ligase activity. More importantly, Ras-induced senescence was
significantly delayed in PIASy-/- MEFs, which was also reflected by their higher levels of
hyperphosphorylated Rb (310). The study also showed that PIASy interacts with both
p53 and Rb. The significance of these interactions was validated by the observation that
the affinity for endogenous p53 and Rb for endogenous PIASy was significantly higher in
bleomycin-induced senescent fibroblasts when compared to pre-senescent cells (310).
Since NORE1A is a critical senescence effector of Ras, and preliminary evidence
suggests that it can regulate the SUMOylation of proteins, it is plausible that NORE1A
may be cooperating with PIASy to promote Ras-induced senescence.
Here we show that NORE1A, in addition to promoting Rb activation by dephosphorylation, can also regulate other key post-translational modifications of Rb. Our
evidence suggests that NORE1A enhances the overall acetylation as well as the
SUMOylation of Rb, though the precise mechanisms are not fully defined. We show that
NORE1A regulates Rb acetylation in a PCAF independent manner. Therefore, we
hypothesize NORE1A mediated acetylation of Rb may be occurring via p300, as HIPK2,
a binding partner of NORE1A, can recruit the acetyltransferase CBP/p300 into a complex
to indirectly promote p53 acetylation (20,291). Thus, it is plausible that NORE1A can
regulate Rb acetylation by a similar mechanism. We also show that NORE1A can
enhance the SUMOylation of Rb. Though the mechanism by which NORE1A affects Rb
SUMOylation remains unknown, we now show that NORE1A forms an exogenous
complex with PIASy, one of the critical SUMO ligases involved in Ras-induced
senescence. This finding does not confirm that PIASy is in fact the player involved in
NORE1A enhanced Rb SUMOylation; however, it does bring up the intriguing
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possibility that NORE1A could be regulating the SUMOylation of a number of proteins,
as Rb is not the only target of PIASy. Lastly, we show that Ras and NORE1A cooperate
to hyper-stabilize Rb, and that the loss of NORE1A leads to a decrease in overall Rb
levels. Collectively, our results suggest that NORE1A regulates the post-translational
modification code of Rb, just as is the case with p53, in order to drive its pro-senescent
function, as well as stabilize the Rb protein, which highlights both a qualitative and
quantitative means of NORE1A regulation of Rb.

4.2 – Results:

Ras/NORE1A enhance the acetylation of Rb – While the activity of Rb is
currently thought to be primarily regulated by its phosphorylation status, Rb can also be
regulated by acetylation (296-298,304). Since NORE1A can activate the pro-senescent
function of p53 by altering its acetylation (20), we sought to determine if NORE1A could
promote the acetylation of Rb. Overall levels of Rb acetylation can be studied by
performing immunoprecipitations using Acetyl-Lysine conjugated beads followed by
western blot analysis for the Rb protein. We observed that in transient transfections of
HEK-293 cells, the over-expression of NORE1A and/or activated Ras promotes the
overall acetylation of Rb (P<0.05), currently believed to be an activating event (Figure
24). The levels of Rb acetylation were elevated in a similar manner in the presence of
NORE1A and activated Ras when compared to Ras/NORE1A individually, likely
because the acetylation machinery has been stimulated to maximum capacity by either
NORE1A or activated Ras over-expression and therefore no further increase is possible.

113

A.

HA-NORE1A:

-

+

-

+

H-Ras-12V:

-

-

+

+

IP: Acetyl-Lysine

IB: Rb

IB: Rb

IB: HA (NORE1A)

8
6

*

*

*

4
2

as
-1
2
N

O

R
E1

A
+H

H

-R

-R

R
E1
O
N

as
-1
2V

V

A

0

Ve
ct
or

B.

Fold Change in Rb Acetylation

IB: Kate (H-Ras-12V)

Figure 24. Ras/NORE1A enhance total Rb acetylation. A. HEK 293 cells were
transfected with HA-NORE1A in the presence or absence of activated H-Ras for 24
hours. Cells were lysed and equal amounts of protein were immunoprecipitated using
acetyl-lysine conjugated beads. The immunoprecipitates were analyzed by western
blotting with anti-Rb, HA, and KATE antibodies. B. Blots were quantified
densitometrically to calculate the fold change in Rb acetylation normalized to total levels
of Rb. *, P<0.05 compared to vector transfected cells.
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NORE1A forms an exogenous, Ras regulated complex with PCAF – While we
have now shown that NORE1A can modulate the acetylation of Rb, it does not address
the mechanism of action. Since NORE1A acts as a scaffolding molecule (20,194), we
hypothesized that NORE1A could be interacting with one of the acetyltransferases
known to regulate Rb acetylation, such as PCAF. We wanted to determine if NORE1A
could be interacting with PCAF, one of the players involved in Rb acetylation (298). We
co-transfected HEK-293T cells with NORE1A and PCAF in the presence or absence of
activated Ras and found that NORE1A coimmunoprecipitated with over-expressed PCAF
in a Ras dependent manner (Figure 25).

Ras/NORE1A modulate Rb acetylation in a PCAF-independent manner – Because
we have shown that NORE1A can modulate the acetylation of Rb and interacts with
PCAF, a known Rb acetyltransferase, we wanted to determine if the ability of NORE1A
to enhance Rb acetylation was occurring via PCAF. We would anticipate that overexpressing PCAF would enhance the ability of NORE1A to promote Rb acetylation. To
address this, we co-transfected HEK-293 cells with NORE1A in the presence or absence
of activated Ras and/or PCAF. Our results suggest that Ras/NORE1A enhance the
acetylation of Rb in a PCAF-independent fashion (Figure 26), as the addition of PCAF in
this system did not affect Ras/NORE1A mediated acetylation of Rb.

Ras/NORE1A enhances Rb SUMOylation – In addition to its regulation by
phosphorylation and acetylation, recent evidence has now shown that Rb can be
modulated by SUMOylation at Lysine 720 (305), and that there may be a link between
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Figure 25. NORE1A forms an exogenous, Ras regulated complex with PCAF. HEK293T cells were transfected with HA-NORE1A and FLAG-PCAF in the presence or
absence of activated H-Ras for 24 hours. Cells were lysed and equal amounts of protein
were immunoprecipitated for FLAG-PCAF, and the immunoprecipitates analyzed by
western blot with anti-HA and anti-FLAG antibodies.
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Figure 26. Ras/NORE1A enhance Rb acetylation in a PCAF-independent manner.
HEK 293 cells were transfected with HA-NORE1A and FLAG-PCAF in the presence or
absence of activated H-Ras for 24 hours. Cells were lysed and equal amounts of protein
were immunoprecipitated using acetyl-lysine conjugated beads. The immunoprecipitates
were analyzed by western blot using anti-Rb, HA, FLAG, and KATE antibodies. Results
suggest that Ras/NORE1A do not cooperate with PCAF to promote Rb acetylation.
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Rb SUMOylation and its pro-senescent function. Since preliminary evidence from the
laboratory had shown that NORE1A may be able to regulate the SUMO modification of
other proteins, we sought to determine if NORE1A could be regulating the SUMOylation
of Rb. To address this, we transiently transfected HEK-293T cells with GFP-Rb and HASUMO-1 in the presence or absence of NORE1A and/or activated H-Ras. By
immunoprecipitating with GFP-conjugated beads and western blotting for HA-SUMO-1,
we can determine the levels of Rb-SUMOylation. Interestingly, our results suggest that
Ras/NORE1A does enhance the SUMOylation of Rb. However, the levels of Rb
SUMOylation were elevated in a similar manner in the presence of NORE1A and
activated Ras when compared to Ras/NORE1A individually (Figure 27). This suggests
that either the ability of NORE1A to enhance Rb SUMOylation might be Ras
independent, or that the SUMOylation machinery has been stimulated to maximum
capacity by NORE1A over-expression and therefore no further increase is possible.

NORE1A forms an exogenous, Ras-regulated complex with PIASy – In order to
elucidate a mechanism of action for NORE1A mediated SUMOylation of Rb, we wanted
to identify potential SUMO ligases that interact with NORE1A, in turn allowing
NORE1A to promote Rb SUMOylation. The most intriguing possibility is the protein
PIASy, an E3 SUMO ligase that has previously been implicated in Ras mediated
senescence (310). To determine if NORE1A interacts with PIASy, we co-transfected
HEK-293T cells with FLAG-PIASy and HA-NORE1A in the presence or absence of
activated H-Ras. We found that NORE1A does form a complex with PIASy, albeit
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Figure 27. Ras/NORE1A enhance Rb SUMOylation. A. HEK-293T cells were
transfected with GFP-Rb, HA-SUMO-1, and FLAG-NORE1A in the presence or absence
of activated H-Ras for 24 hours. Cells were lysed and equal amounts of protein were
immunoprecipitated using anti-GFP. The immunoprecipitates were analyzed by western
blot using anti-HA, FLAG, GFP, and KATE antibodies. B. Blots were quantified
densitometrically to calculate the fold change in Rb SUMOylation. *, P<0.05 compared
to vector transfected cells.
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a weak one; however, the results show that this interaction is enhanced in the presence of
activated Ras (Figure 28), suggesting that this interaction is regulated by Ras.

NORE1A co-localizes with Pc2 in nuclear speckles – Because the significance of
protein SUMOylation has only recently been discovered, far less is known about the
proteins involved in the SUMOylation machinery compared to other post-translational
modifications. To date, there are few proteins that are known to act as E3 SUMO ligases
in addition to the known PIASy. Interestingly, the Polycomb Group protein Pc2 is a
SUMO E3 ligase that has recently been identified, and is found in a subnuclear structure
(nuclear foci) called a Polycomb body (PcG bodies) (311). While Polycomb-group
proteins have been shown to remodel chromatin, little is known about their function.
Work done by David Wotton and colleagues suggests that Pc2 has a much more limited
repertoire than other SUMO E3s, but bring up the possibility that Pc2 represents a
specialized polycomb protein (312). In addition, they demonstrated that although it
appears to have a relatively weak E3 in vitro, Pc2 has robust SUMO E3 activity in vivo
(312), suggesting that its activity may be modulated by adaptor proteins.
Interestingly, recent evidence showed that Pc2 binds to HIPK2, and that these
proteins have an overlapping localization in distinct nuclear speckles. Furthermore, Pc2
serves as a SUMO E3 ligase for this kinase, and this SUMOylation was shown to
enhance the ability of HIPK2 to mediate transcriptional repression (313). Because
NORE1A was shown to regulate HIPK2 activity and is found in similar nuclear
structures than the ones involving Pc2/HIPK2, we hypothesized that NORE1A might be
found to have an overlapping localization with Pc2. To address this, we performed
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Figure 28. NORE1A forms an exogenous, Ras regulated complex with PIASy. HEK293T cells were transfected with HA-NORE1A and FLAG-PIASy in the presence or
absence of activated H-Ras for 24 hours. Cells were lysed and equal amounts of protein
were immunoprecipitated using anti-FLAG. The immunoprecipitates were analyzed by
western blot using anti-HA and anti-FLAG antibodies.
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co-localization experiments using fluorescence microscopy. We transfected COS-7 cells
with GFP-Pc2 and KATE-NORE1A in the presence or absence of activated Ras for
24hours. Indeed, we found that in a vast majority of cells that expressed both proteins,
NORE1A and Pc2 strongly co-localized in distinct nuclear speckles (Figure 29),
suggesting that NORE1A might be regulating the SUMOylation of proteins through its
association with Pc2. However, co-localization does not confirm protein-protein
interaction, and thus must be validated by coimmunoprecipitation. Furthermore, the
presence of activated Ras in a number of cells caused co-localization of NORE1A and
Pc2 along the microtubule network, raising the possibility that Ras may be regulating the
sub-cellular localization of Pc2 via NORE1A, potentially regulating the SUMOylation of
additional proteins in addition to nuclear proteins.

Ras and NORE1A cooperate to stabilize Rb – Post-translational modifications of
proteins, such as acetylation and SUMOylation, have been shown to regulate protein
stability (307,314). Since NORE1A forms an exogenous, Ras regulated complex with Rb,
in turn modulating several key post-translational modifications of Rb, and because we
found slightly elevated levels of Rb in the presence of Ras/NORE1A when performing
experiments throughout this project, we hypothesized that Ras and NORE1A may be
promoting the stability of Rb. To determine the effects of Ras and NORE1A on Rb
stability, HEK-293 cells were transfected with Rb, NORE1A, and activated H-Ras
expression constructs for 24 hours. The cells were then treated with cycloheximide and
were lysed over a time course. The results show that after 8 hours following
cycloheximide treatment, Rb expression is elevated in the presence of NORE1A or
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Figure 29. NORE1A co-localizes with Pc2 in the nucleus. COS-7 cells were
transfected with GFP-Pc2 and RFP-NORE1A in the presence or absence of activated HRas for 24 hours. Fluorescence microscopy analysis revealed that in some cells,
exogenously expressed NORE1A forms nuclear speckles with Pc2, and that activated Ras
promotes additional co-localization onto the microtubule network of the cytoplasm.
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activated Ras (Figure 30). Furthermore, there is a consistent elevation of Rb expression
in the presence of both NORE1A and activated Ras, suggesting that the proteins are
cooperating to promote Rb stability. Further studies using a set of lung epithelial HBEC3KT cells, which we have engineered to be knocked down for NORE1A (20), showed
that suppression of NORE1A acts to destabilize Rb levels (Figure 31). Collectively,
these results suggest that Ras promotes Rb stability via NORE1A.

4.3 – Discussion:

It has been well established that Ras, in addition to its ability to promote
transformation, can induce cellular senescence (159). It is widely believed that such a
mechanism acts as a critical barrier against tumor development. There is now overwhelming evidence pointing to Ras being able to promote senescence through the critical
p53 and Rb pathways, and that in human systems loss of both of these pathways is
required in order for Ras to bypass senescence and promote transformation (169).
However, the mechanisms by which Ras regulates p53 and Rb were not fully understood.
Interestingly, Ras was shown to promote the pro-senescent post-translational
modifications of p53 (281), though how this was taking place remained unknown. It
would seem logical that such tumor suppressive phenotypes would be occurring via
senescence effectors of Ras. It was recently shown that NORE1A is a critical mediator of
Ras-induced senescence. By forming a Ras regulated complex with HIPK2, NORE1A
could scaffold HIPK2 to p53, in turn regulating the pro-senescent post-translational
modifications of p53 (20). These findings provide two novel, and critical, lines of
evidence. First, NORE1A is a critical mediator of Ras-induced senescence. Second,
124

Rb:

+ + + + + + + +
-

-

-

Time (Hrs): 0

4

8 24

NORE1A:

-

+ + + +
0

4

8

24
IB: HA (Rb)
IB: HA (NORE1A)
IB: β-Actin

Rb:
NORE1A:
H-Ras-12V:

+ + + +
- - - + + + +

Time (Hrs): 0

4

8

24

+ +
+ +
+ +

+ +
+ +
+ +

0

8

4

24

IB: HA (Rb)
IB: HA (NORE1A)

IB: KATE (H-Ras-12V)

n.s.*

IB: β-Actin

Figure 30. Ras/NORE1A cooperate to stabilize Rb. HEK 293 cells were transfected
with HA-Rb and HA-NORE1A in the presence or absence of activated H-Ras for 24
hours. The cells were treated with cycloheximide (20 µg/mL) and lysed at the indicated
times after addition of cycloheximide. Levels of Rb protein were measured by western
blot analysis. Shown is a representative blot of two independent experiments.
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Figure 31. Loss of NORE1A destabilizes Rb. A matched pair of HBEC-3KT cells
containing either the scrambled shRNA control or two different NORE1A shRNAs were
generated as previously described (20). Cells were lysed and equal amount of whole cell
lysates were subjected to western blot analysis using an anti-Rb antibody.
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Ras regulates the post-translational modification signature of proteins, including tumor
suppressors such as p53, via NORE1A.
The secondary pathway in Ras-induced senescence involves Rb, another tumor
suppressor that, like p53, is primarily regulated by its post-translational modifications.
We have shown that NORE1A can also promote Ras-induced senescence by regulating
the Rb pathway. Ras can promote NORE1A mediated scaffolding of PP1A onto Rb in
order to activate it via dephosphorylation. However, similar to p53, Rb is regulated by
additional post-translational modifications. While the biological consequence of these
modifications is not as clear as the phosphorylation events, the current evidence suggests
that both the acetylation and SUMOylation of Rb as being activating events.
We have now shown that Ras and NORE1A enhance to overall acetylation of Rb.
However, the mechanism of action remains unclear. Three proteins have been currently
identified as being able to regulate Rb acetylation: PCAF, p300, and Tip60. Interestingly,
we found that NORE1A forms an exogenous complex with PCAF; however, our overexpression studies suggest that the ability of Ras/NORE1A to promote Rb acetylation is
occurring in a PCAF independent manner. A previous report showed that acetylation of
Rb at the C-terminus by p300 maintains Rb in its active, hypophosphorylated form (297).
Interestingly, the kinase HIPK2 has been shown to recruit CBP/p300 to its effector
proteins, such as p53, to regulate their function (291). Because we have previously
established that NORE1A forms an endogenous, Ras regulated complex with HIPK2, in
turn promoting the pro-senescent acetylation of p53 (20), it is possible that NORE1A can
regulate Rb acetylation by a similar mechanism in order to maintain Rb in its active state.

127

In addition to being regulated by phosphorylation and acetylation, Rb can also be
modified by SUMOylation. SUMOylation of proteins is a relatively new concept, but one
that has quickly shown to have drastic effects on protein function, such as protein
stability and affecting protein-protein interactions. While the site for Rb SUMOylation
has been mapped to Lysine 720 (305), the significance of this modification remains
poorly understood. Interestingly, the SUMOylation machinery has been linked to
senescence, as processed forms of SUMO-2/3 promotes senescence in a p53 and Rb
dependent manner (306). Because the link between Rb, SUMOylation, and senescence is
quite unclear, and that prior evidence from our laboratory showed that NORE1A could
modulate the SUMOylation of other proteins, we believed that NORE1A might be
regulating Rb SUMOylation. Indeed, over-expressing Ras/NORE1A did lead to an
increase in the levels of Rb SUMOylation. What remains unknown is the mechanism by
which NORE1A regulates this Rb modification. Currently, there are two intriguing
possibilities that have arisen from our preliminary findings. First, we have shown that
NORE1A forms an exogenous, Ras regulated complex with the E3 SUMO ligase PIASy,
which is already established to play a role in Ras mediated senescence. Furthermore, we
have shown that NORE1A strongly co-localizes with the newly identified E3 SUMO
ligase Pc2, a protein known to regulate HIPK2 SUMOylation, and that activated Ras
seems to affect some of this co-localization to the microtubule network in addition to
nuclear speckles. While both of these potential mechanisms are quite interesting, there is
a substantial amount of work that will need to be performed in order to confirm that one
of these pathways is indeed the mechanism of action for NORE1A mediated Rb
SUMOylation. Even with the possibility of NORE1A regulating Rb SUMOylation
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independently of these potential pathways, the data strongly implicates NORE1A with
the SUMOylation machinery, raising the intriguing possibility that NORE1A could be
mediating the function of a variety of unknown target proteins via SUMOylation.
In addition to being regulated at a qualitative level by post-translational
modifications, Rb can also be regulated from a quantitative perspective, as it has been
shown to be degraded through a proteasome-dependent pathway (315,316). It was later
found that the ubiquitin ligase mdm2 promotes Rb protein degradation via a proteasomedependent pathway (286). We have now shown that Ras and NORE1A cooperate to
stabilize Rb protein, and that the loss of NORE1A destabilizes Rb. NORE1A has been
shown to associate with mdm2 to regulate the stability of other targets (288). Thus, it
would be interesting to determine if NORE1A could be stabilizing Rb by antagonizing
the effects of mdm2 on Rb. In addition, one of the physiological functions of protein
SUMOylation is that it can regulate protein stability (307). Thus, the ability of
Ras/NORE1A to modulate Rb stability might come for the ability to enhance Rb
SUMOylation. It would be interesting to determine if generating a SUMO-deficient Rb
mutant (via site-directed mutagenesis) would show a decrease in stability, even in the
presence of Ras/NORE1A. In parallel, it would also be intriguing to determine what the
outcome of such a mutant might have on NORE1A mediated senescence. However, it is
quite possible that SUMOylated Rb may serve to regulate different Rb functions in
addition to senescence, which may explain why Rb is such a critical tumor suppressor as
well as the reason for its inactivation in such a high percentage in human cancers.
It has been well established that Ras can regulate critical signaling cascades by
phosphorylation and dephosphorylation events (108), suggesting that this may be the
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fundamental mechanism by which Ras modulates its effector proteins. However, we have
recently described a novel mechanism by which Ras, through its effector NORE1A, can
regulate the acetylation of p53 to induce senescence (20). This was the first description
showing that Ras can regulate protein acetylation. Furthermore, we now show evidence
suggesting that Ras can also regulate Rb acetylation via NORE1A. Therefore, it is
reasonable to suggest that Ras mediated protein acetylation may be just as important, if
not more important, than phosphorylation. Indeed, recent proteomics analysis has
identified thousands of acetylated mammalian proteins, which has now given rise to the
“in vivo acetylome” (317). More importantly, a large number of the acetylation sites
identified were present on proteins involved in numerous, vital biological processes, such
as chromatin remodeling, DNA replication, and nuclear transport, suggesting that these
processes may be influenced by such a modification (317). Thus, from a clinical
standpoint, a true understanding of how Ras regulates the “acetylome” will be critical in
terms of evaluating the proper therapeutic approaches for cancer treatments. This is of
particular interest with regards to targeting HDACs or SIRTs using pharmacological
approaches. For example, SIRT1 is over expressed in some cancers harboring Ras
mutations, and targeting SIRT1 has been shown to suppress transformation and sensitize
such cancers to conventional therapy (318). Mechanistically, SIRT1 mediated
deacetylation suppresses the functions of several tumor suppressors, including p53 (302).
Additionally, HDAC inhibitors are another class of anti-cancer agents that are cytotoxic
to cancer cells, and some studies have shown that HDAC inhibitors can activate the proapoptotic ability of oncogenic Ras (319). Ultimately, it will be of utmost importance to
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determine the expression patterns of Ras effectors that play a role in the regulation of the
“acetylome” in order to optimize therapeutic options targeting the acetylation machinery.
Lastly, our data highlights the first example by which Ras can promote the
SUMOylation of proteins. Here, we show that by using its effector NORE1A, Ras can
promote the SUMOylation of Rb, and may be doing so in part by promoting the
interaction of NORE1A with SUMO ligases. While much less is known about protein
SUMOylation compared to other post-translational modifications, the SUMOylation
machinery has now been implicated in several important biological processes, such as the
onset of cellular senescence (307). Collectively, these findings suggest a potential
paradigm shift for Ras action. While it has been clearly shown that Ras regulates several
key signaling pathways by modulation of protein phosphorylation, it now seems as if Ras
can regulate additional post-translational modifications that may be just as critical in
regulating protein function.
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CHAPTER 5

CONCLUSION

Collectively, the work presented in this dissertation highlights a novel mechanism
that explains an unanswered question: how does Ras regulate Rb? It has been known for
over thirty years that while Ras can be powerfully transforming, it can also regulate
growth inhibitory pathways. While it has now been clearly established that Ras can
induce senescence, primarily by activating p53 and Rb, how Ras specifically regulates
the p53 and Rb pathways remained unknown. Our work shows that Ras uses NORE1A as
a senescence effector to regulate powerful tumor suppressors, p53 and Rb, that play
crucial roles in Ras mediated senescence.
We found that NORE1A forms an endogenous, Ras regulated complex with the
phosphatase PP1A. Not only does NORE1A stabilize PP1A, it scaffolds PP1A to Rb in a
Ras dependent manner, in turn activating Rb via dephosphorylation. Furthermore, we
show that NORE1A requires Rb in order to fully promote senescence. These findings,
along with previous work performed in the laboratory, define NORE1A as a double
barreled senescence effector of Ras by regulating pro-senescent post-translational
modifications of p53 and Rb (Figure 32). Loss of NORE1A subverts these two critical
pathways, which allows the Ras mediated growth promoting pathways to predominate, in
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Figure 32. Molecular mechanisms whereby Ras promotes the induction of
senescence via its effector NORE1A. In normal cells, Ras promotes the acetylation of
p53 via the NORE1A/HIPK2 as well as the dephosphorylation of Rb via the
NORE1A/PP1A axis. Together, these pathways serve as a protective barrier against
unrestricted Ras mediated transformation. In the absence of NORE1A (right), the prosenescent functions of p53 and Rb cannot be activated, resulting in the bypass of
senescence induction and allows for the Ras mediated proliferative signals to dominate.
Ac, acetylated lysine; P, phosphorylation.
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turn driving Ras towards transformation. This validates previous findings showing that
Ras driven tumors are frequently associated with reduced NORE1A expression.
Interestingly, PP1A is not an Rb-specific phosphatase, and can modulate the
function of proteins by regulating their phosphorylation status. The specificity of PP1A
for its substrates is dictated by other targeting proteins. Indeed, PP1A can associate with
over two hundred regulatory proteins which can dephosphorylate hundreds of targets.
Our data shows that NORE1A may serve as a PP1A targeting protein. However, our
work has not confirmed whether the NORE1A/PP1A complex specifically targets Rb.
Further experiments will be vital to determine any additional NORE1A targeted
substrates.
In addition to regulating Rb phosphorylation, we found that NORE1A can
regulate additional post-translational modifications of Rb, including acetylation and
SUMOylation. Unlike phosphorylation, the significance of Rb acetylation/SUMOylation
remains poorly understood; however, it is believed that these modifications are activating
events. It will be interesting to determine if these modifications are necessary for Rb
mediated senescence. There is some belief that Rb modifications, such as SUMOylation,
may actually lead to a specific sub-set of Rb protein that perform distinct Rb functions in
addition to the prototypical cell cycle arrest and senescence induction.
This work highlights novel mechanisms by which Ras can regulate protein
acetylation as well as SUMOylation, suggesting the need for a new paradigm for Ras
action. It has been well established that Ras can regulate the function of proteins by
modulating their phosphorylation status. However, our evidence strongly suggests that in
addition to such regulation, Ras can regulate multiple post-translational modifications by
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using its effector proteins, such as NORE1A, to target specific substrates. Therefore, Ras
must be thought of as a critical mediator of protein function by playing a pivotal role in
regulating the post-translational modification code of downstream proteins, including the
previously unidentified modifications of acetylation and SUMOylation.
Throughout the project, we found that Ras/NORE1A stabilize both PP1A and Rb.
These findings were not unexpected for several reasons. First, we had previously shown
that NORE1A can affect the stability of other proteins, such as HIPK2 (20). Second, it
seems logical that if NORE1A is a senescence effector of Ras, it would stabilize the
PP1A/Rb complex in order to activate the pro-senescent functions of Rb. While these
findings are interesting, they do not provide a mechanism of action. Future studies are
crucial to determine the mechanisms by which NORE1A promotes the stability of PP1A
and Rb. One attractive possibility is via the ubiquitin ligase mdm2, for two reasons. First,
mdm2 has been shown to promote tumorigenesis by destabilizing Rb. Second, mdm2 has
been found in an endogenous complex with PP1A. Intriguingly, NORE1A has been
implicated in regulating the degradation of specific mdm2 targets. Thus, NORE1A could
be promoting the stability of both PP1A and Rb by antagonizing the degradation
properties of mdm2.
Some standard therapies invoke a senescence response as part of their therapeutic
effect. Indeed, the concept of pro-senescence therapy has emerged over the recent years
as a novel therapeutic approach to treat cancers, and it is now believed that the inclusion
of deliberate pro-senescence therapy may be critical as part of cancer treatment regimens
(320). Such approaches include drugs that enhance p53 activity and function, as well as
drugs with the ability to modulate Rb activity through targeting Cdks and CDKIs (320).
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Our studies here indicate that the status of NORE1A in a tumor may play a role in
dictating the sensitivity of tumor cells to any pro-senescence type therapy.
As loss of NORE1A expression primarily occurs via promoter methylation, it is a
candidate for epigenetic therapy. It has already been shown that restoring NORE1A
expression in several NORE1A-negative cancer cell lines using the DNA methyltransferase inhibitor 5-Azacytidine restores NORE1A signaling pathways (191).
Unfortunately, treatment with 5-Aza-C results in non-specific overall DNA methylation
and this process may affect multiple regulatory pathways (321). This can likely reactivate
expression of multiple silenced genes, including oncogenes and tumor suppressors in
different cell types and in different cancers (322). However, the continued development
of more specific epigenetic therapy agents, such as Nanaomycin A, which preferentially
inhibits the key DNMT3B enzyme, may enhance the practicality of this approach. Recent
evidence has shown that Nanaomycin A reduced global methylation levels while
reactivating transcription of several RASSF family members (323,324), though its effects
on NORE1A expression have not yet been studied. Thus, a novel approach in NORE1A
negative cancers might be to combine epigenetic therapy with senescence therapy to
induce tumor regression.
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